Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год
Применить Всего найдено 2548. Отображено 100.
02-05-2013 дата публикации

Compositions and methods for treating full thickness burn injuries

Номер: US20130108670A1
Автор: Jeffrey S. Guy, Samuel Eugene Lynch
Принадлежит: Biomimetic Therapeutics LLC

The present invention provides compositions and methods for treating full thickness burn injuries. The present invention provides compositions and methods for promoting healing and regeneration of impaired or damaged tissue at a site of such a full thickness burn injury, as well as promoting vascularization and angiogenesis in regenerating tissue at such sites.

Подробнее
Номер записи: 1
25-07-2013 дата публикации

Medical Devices, Wound Dressings, and Methods for Dressing Wounds

Номер: US20130189339A1
Автор: Vachon David J.
Принадлежит:

Medical devices, wound dressings, and methods of dressing wounds are described. Devices and methods using silicone and pharmaceutically active agents are described. Devices including covers and bases are described. 1. A medical device comprising:a component configured to be coupled to a recipient, the component having at least one surface configured to abut at least one surface of the recipient; anda tacky silicone layer residing on at least a portion of the one surface of the component, the tacky silicone layer comprising polystyrene sulfonate material distributed therein.2. The medical device of wherein the polystyrene sulfonate material comprises silver polystyrene sulfonate (cross-linked” and non-cross-linked).3. The medical device of wherein the polystyrene sulfonate material comprises salts of polystyrene sulfonate.4. The medical device of wherein the component comprises wound dressing fabric.5. The medical device of wherein the wound dressing is substantially planar.6. The medical device of wherein the component is configured as a frame having at least one opening within the frame claim 1 , the tacky silicone layer residing along a perimeter of the frame.7. The medical device of wherein the component is configured to engage at a portion of an epidermis of a patient claim 1 , the patient being the recipient.8. The medical device of wherein the tacky silicone layer further comprises additional pharmaceutically active agents.9. The medical device of wherein the pharmaceutically active agents include one or more of antimicrobial claim 8 , anti-inflammatory claim 8 , and/or antiproteolytic agents.10. A medical device comprising:a component configured to be coupled to a recipient, the component having at least one surface configured to abut at least one surface of the recipient; anda tacky silicone layer residing on at least a portion of the one surface of the component, the tacky silicone layer comprising silver-organo complex material distributed therein.11. The ...

Подробнее
Номер записи: 2
26-09-2013 дата публикации

HEMOSTATIC MATERIAL CONTAINING NANO-FIBER CONTAINING SYNTHETIC COLLAGEN

Номер: US20130251780A1
Автор: KATAOKA YUKINORI, Kobayashi Hisatoshi, SHIMATANI AKIKO, Terada Dohiko, TODOKORO MASAMI
Принадлежит: JNC CORPORATION

A hemostatic material as a high-performance medical material is described, which is capable of stopping bleeding in short time and is easy to handle and produce. The hemostatic material contains a nano-fiber that contains: a polymer, and a polypeptide having a peptide fragment represented by formula (1): 2. The hemostatic material of claim 1 , wherein a content of the polypeptide in the nano-fiber ranges from 2.5 wt % to 90 wt %.3. The hemostatic material of claim 1 , wherein the polymer comprises at least one selected from the group consisting of natural collagen claim 1 , polyethylene glycol claim 1 , polyvinyl alcohols and polyglycolic acids.4. The hemostatic material of claim 1 , wherein the nano-fiber is in a form of a nonwoven fabric.5. The hemostatic material of claim 4 , wherein a support base material is laminated on the nonwoven fabric.6. The hemostatic material of claim 5 , wherein the support base material comprises a polyurethane. This application claims the priority benefit of Japan Application No. 2012-067629, filed on Mar. 23, 2012. The entirety of the above-mentioned patent application is hereby incorporated by reference herein and made a part of this specification.1. Field of InventionThis invention relates to a hemostatic material, and particularly to a hemostatic material that contains a nano-fiber containing a synthetic collagen.2. Description of Related ArtA fiber having a nanometer-scale diameter (1 nm to 1000 nm) exhibits different material properties as compared to fibers having micrometer-scale or larger diameters, and is generally called a nano-fiber to distinguish from other fibers. For a nano-fiber has a very large surface area per unit weight, that is, a very large specific surface area, its applications in carrier materials of functional molecules, fluid-contact reaction materials, cloth materials, industrial material products, living material products, environmental material products, electrodes and membranes of fuel cells and ...

Подробнее
Номер записи: 3
31-10-2013 дата публикации

SOLID DRESSING FOR TREATING WOUNDED TISSUE

Номер: US20130287837A1
Автор: BEALL Dawson, MACPHEE Martin
Принадлежит:

Disclosed are solid dressings for treated wounded tissue in mammalian patients, such as a human, comprising a haemostatic layer consisting essentially of a fibrinogen component and a fibrinogen activator, wherein the haemostatic layer(s) is cast or formed from a single aqueous solution containing the fibrinogen component and the fibrinogen activator. Also disclosed are methods for treating wounded tissue using these dressings and frozen compositions useful for preparing the haemostatic layer(s) of these dressings. 1. A solid dressing comprising a solid haemostatic layer wherein said solid haemostatic layer comprises dried fibrinogen component and thrombin , said dried fibrinogen and thrombin being dried from a single aqueous mixture of fibrinogen and thrombin.2. A solid dressing comprising a haemostatic layer comprising substantially unreacted fibrinogen component and thrombin , wherein said fibrinogen component and said thrombin are dried from a single aqueous solution forming said solid haemostatic layer; and wherein said fibrinogen component and thrombin within the solid are substantially unreacted until said solid dressing comes into contact with an aqueous fluid.3. The solid dressing of comprising at least two haemostatic layers.4. The solid dressing of or claim 1 , further comprising at least one support layer.5. The solid dressing of claim 4 , wherein said support layer comprises a backing material.6. The solid dressing of claim 4 , wherein said support layer comprises an internal support material.7. The solid dressing of claim 4 , wherein said support layer comprises a resorbable material.8. The solid dressing of claim 4 , wherein said support layer comprises a non-resorbable material.9. The solid dressing of claim 7 , wherein said non-resorbable material is selected from the group consisting of silicone polymers claim 7 , paper claim 7 , gauze and latexes.10. The solid dressing of claim 4 , further comprising at least one physiologically acceptable adhesive ...

Подробнее
Номер записи: 4
23-01-2014 дата публикации

SILICONE GEL-BASED COMPOSITIONS FOR WOUND HEALING AND SCAR REDUCTION

Номер: US20140023610A1
Автор: "WILSON NiKita", PALEFSKY Irwin
Принадлежит: VALEANT PHARMACEUTICALS INTERNATIONAL

This invention is a composition comprising a cyclic siloxane, a silicone occlusive fluid, a silicone occlusive gel, and a silicone resin powder. The composition is useful for wound healing. 1. A method for the treatment of wounds to reduce scaring comprising administering to a patient in need thereof a composition comprising:a. a cyclic siloxane;b. a silicone occlusive fluid;c. a silicone occlusive gel; andd. a silicone resin powder.2. The method of claim 1 , wherein the composition further comprises an ascorbic acid ester or salt thereof. This application claims priority under 35 U.S.C. §119(e) to U.S. Provisional application Ser. No. 60/997,166, filed Sep. 30, 2007, the entire contents of which is incorporated herein by reference.The present invention relates to compositions containing various silicone compounds, which are suitable for promoting the healing of skin wounds and for the prevention of scarring.Significant skin wounds, such as are caused by injury or surgery, frequently lead to scarring. Scarring in many instances results in a diminished sense of touch, loss of flexibility and loss of range of motion (where scars run across joints). Scarring also results in obvious cosmetic problems, particularly when on the face and hands. Skin wounds are also pane to infection, and even with conventional dressings, infections are fairly common. Burn victims are particularly susceptible to infections, and can be left with severe scarring when the wounds heal. There is a need for methods of treatment of skin injuries that minimize or eliminate scar formation.Conventional wound dressings, such as are made from cotton gauze and various polymers, leave much to be desired, especially when a large area of skin must be dressed. The ability of the dressing to remain in place and protect the wound becomes progressively more compromised as the area of the wound increases, while at the same time the removal the dressing without injury to the underlying tissue becomes ...

Подробнее
Номер записи: 5
07-01-2021 дата публикации

DEVICES FOR DETECTING AND/OR IDENTIFYING MICROBIOLOGICAL INFECTIONS, FOR NON-IMPLANTABLE MEDICAL DEVICES

Номер: US20210000409A1
Автор: BERRAT Fanny, DARDY Aline, ROZAND Christine
Принадлежит: BIOMERIEUX

A biosensor intended to be integrated in the actual structure of a dressing, a compress or any other similar absorbent article. This biosensor makes it possible to monitor the onset of a microbiological infection of a wound and/or of a skin lesion. The biosensor includes a piece of absorbent hydrophilic material on which, on the surface and/or within the thickness thereof, a composition of agglomerated powders is immobilized, the composition including ethylene-vinyl acetate (EVA) particles having a surface partially coated at least with a salt of orthophosphoric acid and a visual indicator of microbiological growth. 1. A biosensor comprising a piece of absorbent hydrophilic material on which , on the surface and/or within the thickness thereof , a composition of agglomerated powders is immobilized , said composition comprising ethylene-vinyl acetate (EVA) particles having a surface partially coated at least with a salt of orthophosphoric acid and a visual indicator of microbiological growth.2. The biosensor as claimed in claim 1 , in which the salt of orthophosphoric acid is selected from potassium dihydrogen phosphate (KHPO) and sodium dihydrogen phosphate (NaHPO).3. The biosensor as claimed in claim 1 , in which EVA and KHPOare present in a KHPO/EVA weight ratio between 1:25 and 1:8.4. The biosensor as claimed in claim 1 , in which EVA and NaHPOare present in an NaHPO/EVA weight ratio between 1:15 and 1:3.5. The biosensor as claimed in claim 1 , in which the EVA has a vinyl acetate content by weight from 10 to 40%.6. The biosensor as claimed in claim 1 , in which the surface of the EVA particles is also coated with a gelling agent.7. The biosensor as claimed in claim 6 , in which the gelling agent is selected from agar claim 6 , agarose claim 6 , guar gum and xanthan gum.8. The biosensor as claimed in claim 1 , in which the surface of the EVA particles is also coated with MnCl.9. The biosensor as claimed in claim 1 , in which the surface of the EVA particles is ...

Подробнее
Номер записи: 6
07-01-2016 дата публикации

FORMATION OF SEMI-PERMEABLE POROUS ARTIFICAL SCAB

Номер: US20160000963A1
Автор: Battista Miguel Edgardo, VEGA VILLAVICENCIO Parsival
Принадлежит:

Pourous semi-ermeable artificial self-attaching scab designed to protect the eroded or injured surfaces. 1. (canceled)2. An aqueous thixotropic fluid , comprising:1-5 weight % of azosulfamide, 0.004-0.007 weight % of gentian violet, 0.001-0.003 weight % of dexamethasone, 0.5-2 weight % of panthenol, and 0.03-0.06 weight % of gentamycin.3. The fluid according to claim 2 , wherein it is used topically as cicatrizing agent.4. The fluid according to claim 2 , wherein it is used for treating at least one of lesions claim 2 , wounds or burns. The present invention relates to artificial cicatrization means by means of which a substance is applied to the damaged surfaces, wounds, burns A-AB, after removing the necrotic tissue and disinfecting the damaged or burnt zone.The technique consists of the removal of the necrotic tissue from the injured zone and subsequent application of the artificial covering mentioned in the title. The preparation causes the formation of an artificial scab on the injured surface.The problems to be solved are:1. To replace the use of gauzes since they adhere to the damaged zone and cause lesions in the granulation zone when an attempt is made to remove them, thus causing defective cicatrizations.2. To avoid potential infections given that protection against external biological agents is provided.3. To avoid the loss of body fluids and heat, resulting from the loss of the integrity of the mechanical barrier.The porous artificial scab allows the formation of new tissue, allowing its natural respiration: during its regeneration and bringing about a faster development of cicatrization by avoiding disrupted processes such as the necrosis or the development of anaerobes, without the need to cover and without performing further treatments until the natural detachment of the “Scab.”*To protect the lesion against infections and losses of fluids with an artificial scab, and thus the cicatrization is much more rapid and the new tissue is not defective.*The ...

Подробнее
Номер записи: 7
07-01-2021 дата публикации

WOUND-TREATING ABSORBENT

Номер: US20210001003A1
Автор: I Michael Tung Kiung, KRONGAUZ Vadim Valerievich, Ling, XIE Wei
Принадлежит:

The present disclosure provides wound-treating absorbent kits that comprise a set of hemostatic compositions including at least (1) a first hemostatic composition including a first crosslinked polysaccharide selected from the group consisting of cyclodextrin and dextran, and (2) a second hemostatic composition including a second crosslinked polysaccharide selected from the group consisting of cyclodextrin and dextran. In some embodiments, the first hemostatic composition has a first degree of crosslinking, and the second hemostatic composition has a second degree of crosslinking higher than the first degree of crosslinking. Also provided are methods of treating a wound by selecting a hemostatic composition from the disclosed set of hemostatic compositions, and administering the selected hemostatic composition to a site of the wound. 1. A wound-treating absorbent kit comprising:a set of hemostatic compositions including at least (1) a first hemostatic composition including a first crosslinked polysaccharide selected from the group consisting of cyclodextrin and dextran, wherein the first hemostatic composition has a first degree of crosslinking, and (2) a second hemostatic composition including a second crosslinked polysaccharide selected from the group consisting of cyclodextrin and dextran, wherein the second hemostatic composition has a second degree of crosslinking higher than the first degree of crosslinking.2. The wound-treating absorbent kit of claim 1 , wherein each of the first and second hemostatic compositions includes crosslinked β-cyclodextrin.3. The wound-treating absorbent kit of claim 1 , wherein each of the first and second hemostatic compositions is in powdered form.4. The wound-treating absorbent kit of comprising a pharmaceutically acceptable diluent for reconstitution of any of the first and second hemostatic compositions.5. The wound-treating absorbent kit of claim 1 , wherein each of the first and second hemostatic compositions comprises a ...

Подробнее
Номер записи: 8
27-01-2022 дата публикации

GEL, IN PARTICULAR FOR USE IN A WOUND TREATMENT AGENT

Номер: US20220023492A1
Автор: Hess Marco
Принадлежит: SANIXTREME GMBH & CO KG

A gel is to be disclosed, in particular for use in a wound treatment composition, with which a particularly high storage stability and long-term stability can be achieved with high microbiocidal activity. For this purpose, the gel according to the invention comprises an inorganic silicate as thickener and an electrochemically activated starting saline solution which has a free chlorine content of more than 300 mg/l. In addition, a colored gel having the properties described above can be obtained by adding suitable pigments. 1. Use of an electrochemically activated saline solution which has a free chlorine content of more than 300 mg/l and a redox potential of between 600 and 1000 mV , preferably between 700 and 900 mV , particularly preferably of about 800 mV , for the production of a gel which comprises , as thickener , an inorganic layered silicate in whose layers hydroxide anions are incorporated.2. Use according to claim 1 , wherein the starting saline solution has a pH between 6 and 8 claim 1 , preferably of about 7.3. Use according to or claim 1 , wherein the starting saline solution has a free chlorine content of more than 500 mg/l claim 1 , preferably of more than 600 mg/l.4. Gel obtained by the use according to any one of to .5. Gel according to claim 4 , wherein the mixing ratio thickener/saline solution is between about 1 and about 25% by weight.6. Gel according to or claim 4 , wherein as thickener is provided a lithium magnesium sodium silicate claim 4 , particularly preferably Laponite®.7. Gel according to any one of to claim 4 , having a pH of at least 8 claim 4 , preferably of 9 claim 4 , and/or a viscosity of between 4500 and 6500 mPa claim 4 , preferably of about 5500 mPa.8. Colored gel according to any one of to claim 4 , wherein the mixing ratio pigment/saline solution is between about 0.1 and about 2% by weight.9. The colored gel of claim 8 , wherein the pigment is one or more of Symrise Green C.I. 74260 claim 8 , Merck Rona Colorona Majestic ...

Подробнее
Номер записи: 9
08-01-2015 дата публикации

BIODEGRADABLE NON-WOVEN MATERIAL FOR MEDICAL PURPOSES

Номер: US20150010612A1
Автор: Copanaki Ekaterini, Grafahrend Dirk, Neumüller Daniel, Reibel Denis, VOGT Sebastian
Принадлежит:

The invention relates to a biodegradable fleece containing (i) at least one polymer for inducing primary haemostasis, (ii) at least one non-proteinogenic, low-molecular, water-soluble activator of secondary haemostasis, and (iii) at least one non-proteinogenic, low-molecular, water-soluble inhibitor of fibrinolysis. The invention also relates to a method for producing a biodegradable fleece, in which (i) a fluidised fiber raw material, and additives if applicable, is placed in a container, (ii) the container is made to rotate, (iii) the fluidised fiber raw material is dispensed from the container by means of centrifugal forces, whereby fibers or filaments are formed, and (iv) a biodegradable fleece is produced from the fibers or filaments. The invention also relates to the use of said biodegradable fleece as a local haemostatic agent. 1. Biodegradable fleece , comprising:(i) at least one polymer for inducing primary haemostasis;(ii) at least one non-proteinogenic, low-molecular, water-soluble activator of secondary haemostasis; and(iii) at least one non-proteinogenic, low-molecular, water-soluble inhibitor of fibrinolysis.2. Biodegradable fleece according to claim 1 , wherein the fleece comprises at least one anti-infective agent.3. Biodegradable fleece according to claim 1 , wherein the fleece comprises fibers (1) claim 1 , whereby the fibers (1) of the fleece comprise (i) the at least one polymer for inducing primary haemostasis claim 1 , (ii) the non-proteinogenic claim 1 , low-molecular claim 1 , water-soluble activator of secondary haemostasis claim 1 , (iii) the non-proteinogenic claim 1 , low-molecular claim 1 , water-soluble inhibitor of fibrinolysis and/or claim 1 , optionally claim 1 , at least one anti-infective agent.4. Biodegradable fleece according to claim 1 , wherein the fleece is dry and the average mesh width between the fibers (1) of the dry fleece is at least 50 μm.5. Biodegradable fleece according to claim 1 , wherein the polymer inducing ...

Подробнее
Номер записи: 10
17-01-2019 дата публикации

Dry Composition Comprising An Extrusion Enhancer

Номер: US20190015546A1
Автор: Larsen Kristian
Принадлежит:

Disclosed is a dry composition comprising one or more polyols, which upon addition of an aqueous medium forms a substantially homogenous paste suitable for use in haemostasis procedures. The paste reconstitutes spontaneously upon addition of the liquid; hence no mechanical mixing is required for said paste to form. The composition may further comprise an extrusion enhancer, such as albumin. Also disclosed are methods of preparing said dry composition, a paste obtained from said dry composition and uses of said dry composition or paste for medical and surgical purposes. 1. A dry composition suitable for use in haemostasis and wound healing comprising a frozen paste that has been freeze-dried , said dry composition comprising a biocompatible polymer , an extrusion enhancer and one or more polyols , wherein the dry composition is obtained by the method comprising sequentially:a) providing a cross-linked biocompatible polymer in powder form, one or more polyols selected from sugar alcohols or sugars, an extrusion enhancer and an aqueous medium;b) mixing the biocompatible polymer, the one or more polyols, the extrusion enhancer and the aqueous medium to obtain a paste; and 'wherein the dry composition comprises from about 10% w/w to about 60% w/w of the one or more polyols, and wherein upon addition of an aqueous medium, the dry composition reconstitutes to form a paste without mechanical mixing.', 'c) freeze-drying the paste,'}2. The dry composition according to claim 1 , wherein the extrusion enhancer is selected from albumin claim 1 , phosphatidylcholine claim 1 , phosphatidylserine claim 1 , lecithin or soy bean oil.3. The dry composition according to claim 1 , wherein the dry composition comprises from about 0.3% w/w to about 30% w/w of the extrusion enhancer.4. The dry composition according to claim 1 , wherein the biocompatible polymer is obtained from a cross-linked sponge.5. The dry composition according to claim 1 , wherein the biocompatible polymer is gelatine ...

Подробнее
Номер записи: 11
15-01-2015 дата публикации

FOAMED BIOCOMPATIBLE MATERIALS FOR TISSUE REPAIR

Номер: US20150018280A1
Автор: Hsu Pei-Chi, Liang Huang-Chien, LIAO Chun-Jen, SU YI-CHUN, Tseng Sheng-Hong
Принадлежит:

A foamed biocompatible material for use in tissue repair and a kit for producing same. The kit includes a container having a valve and an inlet, and a tissue-repair composition containing a biocompatible material and a liquid carrier, in which the composition is placed in the inlet of the container and the inside of container has a pressure lower than that of the outside so that, upon opening the valve, the composition is forced into the container by the pressure difference to form a foam inside the container. Also disclosed is a method of preparing a foamed biocompatible material for tissue repair. 1. A foamed biocompatible material produced by a method comprising:providing a container configured to sustain a high pressure such that the container has an internal pressure of greater than 1 atm and less than 250 atm, wherein the container includes a valve, a nozzle, and a tissue-repair composition containing a s neutralized and homogeneous solution at pH 6-8 that includes a biocompatible material, wherein the biocompatible material consists of collagen at a concentration of 1%-10%, a liquid carrier that is water, physiological saline, or phosphate buffered saline, and a gas that is air, oxygen, nitrogen, or carbon dioxide; andopening the valve to release from the nozzle a foam formed of the tissue-repair to composition.2. The foamed biocompatible material of claim 1 , wherein the biocompatible material is not cross-linked3. The foamed biocompatible material of claim 1 , wherein the biocompatible material is a polypeptide claim 1 , a polysaccharide claim 1 , or a combination thereof.4. The foamed biocompatible material of claim 3 , wherein the biocompatible material is collagen claim 3 , hyaluronic acid claim 3 , or a combination thereof.5. The foamed biocompatible material of claim 1 , wherein the foamed biocompatible material has pores less than 250 μm in diameter and a pore density higher than 70%.6. The foamed biocompatible material of claim 5 , wherein the ...

Подробнее
Номер записи: 12
21-01-2021 дата публикации

MEANS AND METHODS FOR WOUND HEALING

Номер: US20210015965A1
Автор: HOSTE Ester, MEES Maarten, THIELEMANS Wim
Принадлежит:

The present invention relates to compositions and methods for tissue regeneration, particularly for treating skin lesions, such as wounds. The invention provides topical plasters and wound healing compositions. Specifically, the invention provides hydrogels compositions of glycyrrhizinic acid analogues. The compositions and methods of the invention are useful especially for assisting the process of wound healing, particularly chronic open lesions that are slow to heal or resistant to healing. 3. A hydrogel according to claim 1 , wherein said wound comprises a decubitus ulcer claim 1 , a chronic ulcer and a diabetic ulcer.4. A hydrogel according to claim 1 , whereby the hydrogel is without bis-methoxy PEG-13 PEG-438/PPG-110 SMDI copolymer (EG56 polymer).5. A hydrogel according to claim 1 , whereby the hydrogel is formed by gelation of 2.5%-25% of glycyrrhizic acid.6. A hydrogel according to claim 1 , whereby the hydrogel has a viscosity of has a viscosity of >10Pa as measured by an Anton Paar Rheometer MCR 501 at 37° C.7. A hydrogel according to claim 1 , which has a temperature lower than 40° C.8. A hydrogel according to claim 1 , the hydrogel consisting of 3.5%-25% of glycyrrhizic acid and water.10. A hydrogel according to claim 1 , whereby the de-gelation point of the hydrogel to be treated on a wound is higher than the body temperature of the mammal so that the hydrogel does not become liquid.11. The topical plaster comprising a hydrogel according to claim 9 , whereby the de-gelation point of the hydrogel to be treated on a wound is higher than the body temperature of the mammal so that the hydrogel does not become liquid.12. A hydrogel according to claim 2 , whereby the de-gelation point of the hydrogel to be treated on a wound is higher than the body temperature of the mammal so that the hydrogel does not become liquid. The present invention relates to the field of tissue regeneration, particularly the field of skin lesions such as wounds. The invention ...

Подробнее
Номер записи: 13
16-01-2020 дата публикации

DEVICE FOR DELIVERY OF POWDERED HEMOSTATIC AGENTS

Номер: US20200016292A1
Автор: BARRY John Joseph Anthony, Fulghum Timothy Michael, HOLSCHER Russel L., SANDERS Paul Jeffrey
Принадлежит:

The disclosure provides a multilayered hemostatic device including a first layer including carboxymethyl cellulose, a second layer including a powdered hemostatic agent provided on the first layer, and a third layer including at least one of gauze, oxidized cellulose, or collagen provided on the second layer, wherein the first layer and the third layer encapsulate the second layer and the hemostatic agent comprises one of fibrinogen, thrombin, fibrin monomers, or the combination of thrombin and gelatin. 1. A multilayered hemostatic device comprising:a first layer comprising carboxymethyl cellulose;a second layer comprising a powdered hemostatic agent provided on the first layer; anda third layer comprising at least one of gauze, oxidized cellulose, or collagen provided on the second layer, wherein the first layer and the third layer encapsulate the second layer,wherein the hemostatic agent comprises one of fibrinogen, thrombin, fibrin monomers, or the combination of thrombin and gelatin.2. The multilayered hemostatic device of claim 1 , wherein the powdered hemostatic agent is a solid particulate.3. The multilayered hemostatic device of or claim 1 , wherein the powdered hemostatic agent is provided on the first layer in a repeating pattern.4. The multilayered hemostatic device of any one of the preceding claims claim 1 , wherein the first layer and the third layer have perimeter edges and the first layer and third layer are sealed along the perimeter edges.5. The multilayered hemostatic device of claim 4 , wherein the perimeter edges of the first layer and the third layer are heat sealed.6. The multilayered hemostatic device of claim 4 , wherein the perimeter edges of the first layer and the third layer are solvent sealed.7. The multilayered hemostatic device of any one of the preceding claims claim 4 , wherein the first layer is soluble under physiological conditions claim 4 , such that the first layer will dissolve when in contact with a fluid from a wound.8. The ...

Подробнее
Номер записи: 14
26-01-2017 дата публикации

COMPOSITIONS FOR TREATING WOUNDS

Номер: US20170021054A1
Автор: Lynch Samuel E., Wisner-Lynch Leslie
Принадлежит:

Novel compositions for treating wounds and promoting the healing thereof are described, including composition containing novel combinations of a carrier and recombinant platelet derived growth factor having fewer isoforms and enhanced biostability. Methods of treating wounds with novel therapeutic composition using dosing procedures leading to effective results with a minimal number of treatment applications are also described. 1. A therapeutic composition comprising sterile rhPDGF and a sterile porous matrix , wherein:(a) the rhPDGF comprises rhPDGF-BB combined with a physiologic solution resulting in a therapeutic solution yielding between about 0.05 mg/ml to about 5 mg/ml of rhPDGF-BB wherein at least 80% of the rhPDGF-BB is unclipped rhPDGF-BB;(b) prior to forming the therapeutic solution the rhPDGF-BB is biostable and the rhPDGF-BB is capable of retaining at least 80% of its bioactivity when stored at 16-32° C. for at least about six months;(c) the matrix includes pores that allow for cell attachment and ingrowth into said pores, and wherein said pores entrap at least about 50% of said rhPDGF within said pores; and{'sup': 3', '3', '3', '3, '(d) the ratio of the rhPDGF solution to the matrix is between about 0.1 ml PDGF solution/cmof matrix to about 1 ml PDGF solution/cmof matrix, or the ratio of the rhPDGF to the matrix is between about 75 μg PDGF/cmof matrix to about 750 μg PDGF/cmof matrix.'}2. (canceled)3. (canceled)4. The therapeutic composition of wherein the therapeutic solution is formed from a sterile rhPDGF powder containing lyophilized rhPDGF-BB wherein at least about 80% of said lyophilized rhPDGF-BB on a weight basis is unclipped lyophilized rhPDGF-BB.5. The therapeutic composition of wherein the physiologic solution comprises rhPDGF-BB sterile water claim 1 , saline claim 1 , or a buffer.7. (canceled)8. (canceled)9. The composition of wherein the carrier is a natural polymer selected from the group consisting of collagen claim 6 , gelatin claim 6 , ...

Подробнее
Номер записи: 15
22-01-2015 дата публикации

COMPOSITION AND DRESSING WITH NITRIC OXIDE

Номер: US20150024029A1
Автор: Araya Abraham, Broderick Sonya Theresa, Minihan Alan Reginald, Robbins Paul Matthew, Waring Michael J.
Принадлежит:

A dressing composition for use as a skin dressing comprises an elastomeric-adhesive composition, and a zeolite comprising releasably adsorbed nitric oxide. The zeolite may comprise a transition metal cation such as Co, Fe, Mn, Ni, Cu, Zn, Ag or a mixture thereof as an extra-framework metal cation, preferably Zn. The elastomeric adhesive composition may be a hydrocolloid-adhesive composition comprising, hydrocolloid and elastomer. The dressing composition releases nitric oxide, which may have beneficial effects, when used on wounds or moist skin, with a substantially constant release rate over a long period of time. A dressing including a layer of the dressing composition has a backing layer and may have a release liner removably attached to the skin-contacting surface of the dressing layer. 118-. (canceled)19. A nitric oxide-releasing dressing composition for use as a skin dressing comprising:i) an elastomeric-adhesive composition, andii) a zeolite dispersed within the elastomeric-adhesive composition, said zeolite comprising releasably adsorbed nitric oxide and a zinc metal cation as an extra-framework metal cation providing positive charge,wherein the dressing composition releases nitric oxide at a generally uniform rate over an extended time period.20. The composition of comprising from 99.5 to 30% by weight of an elastomeric-adhesive composition claim 19 , and from 0.5 to 70% by weight of zeolite.21. The composition of wherein the zeolite is selected from the group consisting of zeolite P claim 19 , zeolite A claim 19 , zeolite X claim 19 , zeolite Y and mixtures thereof.22. The composition of wherein the zeolite is zeolite A.23. The composition of wherein 20 molar % or more of the extra framework cation of the zeolite is a zinc metal cation.24. The composition of wherein 50 molar % or more of the extra framework cation of the zeolite is a zinc metal cation.25. The composition of wherein the zeolite comprises at least 0.5 mmol/g of releasably adsorbed nitric ...

Подробнее
Номер записи: 16
17-04-2014 дата публикации

ANTIMICROBIAL MULTILAYER WOUND DRESSING

Номер: US20140107555A1
Автор: Patel Harish
Принадлежит: COVIDIEN LP

A wound dressing includes one or more layers containing an antimicrobial agent and optionally at least one of: a chelating agent, a second antimicrobial agent, a zinc-containing agent, a cell-signaling agent, and an additional active ingredient or agent. 1. A multi-layer wound dressing comprising:at least one interior layer of hydrophilic material having polyhexamethylene biguanide (PHMB) or a PHMB derivative in an amount of at least about 5,000 ppm; anda first outer layer of hydrophobic material adjacent the at least one interior layer.2. The dressing of claim 1 , wherein the at least one interior layer is constructed to prevent elution of PHMB or PHMB derivatives into adjacent layers of the wound dressing and/or into the skin or wound bed.3. The dressing of claim 1 , wherein the PHMB or PHMB derivative is releasably contained in the interior layer.4. The dressing of claim 1 , wherein the at least one interior layer has at least about 10 claim 1 ,000 ppm of PHMB or PHMB derivative.5. The dressing of claim 1 , further comprising a second outer layer of hydrophobic material.6. The dressing of claim 6 , wherein at least one of the first and second outer layers is dissolvable or absorbable.7. The dressing according to claim 6 , wherein the PHMB or PHMB derivative is coated on the at least one interior layer.8. The dressing of claim 1 , wherein the at least one interior layer has at least about 13 claim 1 ,000 ppm of PHMB or PHMB derivative.9. The dressing of claim 1 , further comprising a therapeutic agent claim 1 , an organoleptic agent claim 1 , a growth factor claim 1 , an analgesic claim 1 , a tissue scaffolding agent claim 1 , a haemostatic agent claim 1 , a protein inhibitor claim 1 , collagen claim 1 , enzymes claim 1 , an anti-thrombogenic agent claim 1 , an anesthetic claim 1 , an anti-inflammatory agent claim 1 , an anticancer agent claim 1 , a vasodilation substance claim 1 , a wound healing agent claim 1 , an angiogenic agent claim 1 , an angiostatic agent ...

Подробнее
Номер записи: 17
29-01-2015 дата публикации

NITRIC OXIDE-GENERATING SKIN DRESSINGS

Номер: US20150030702A1
Автор: Jezek Jan, Watson Lynne Patricia
Принадлежит:

A skin dressing is provided comprising a first component including a source of protons, a second component including a nitrite salt, the skin dressing further comprising a non-thiol reductant. The skin dressing is adapted, such that, when the first and second components are brought together and applied to a skin site the nitrite reacts to generate nitric oxide, increasing the pH of the dressing in contact with the skin site from an acidic value to a more neutral value.

Подробнее
Номер записи: 18
04-02-2016 дата публикации

PEPTIDE-ALBUMIN HYDROGEL PROPERTIES AND ITS APPLICATIONS

Номер: US20160030629A1
Автор: Huang Hongzhou, Nguyen Thu Annelise, Sun Xiuzhi S.
Принадлежит:

Peptide-albumin hydrogels having a self-assembling, -dimensional nanofiber matrix are described. The nanofiber matrix comprises an amphiphilic peptide and albumin. The peptide comprises a terminal hydrophobic region, a central turning region, and a terminal hydrophilic region. Methods of making such hydrogels are also described, along with methods of using the hydrogels as scaffolding for tissue engineering, as 3-dimensional cell cultures, and for drug delivery, encapsulation of active agents (therapeutic cells, molecules, drugs, compounds), cell transplantation, cell storage, virus culture and storage. 1. A peptide-albumin hydrogel having a self-assembling , 3-dimensional nanofiber matrix , said nanofiber matrix comprising an amphiphilic peptide and albumin , wherein said peptide comprises a terminal hydrophobic region , a central turning region , and a terminal hydrophilic region.2. The peptide-albumin hydrogel of claim 1 , wherein said hydrogel is reversible.3. The peptide-albumin hydrogel of claim 2 , wherein said hydrogel has a % recovery of at least about 60% in less than about 10 minutes after destruction of said 3-dimensional nanofiber matrix by shear thinning4. The peptide-albumin hydrogel of claim 1 , wherein said hydrogel has a storage modulus of from about 50 Pa to about 10 claim 1 ,000 Pa at a pH of about 7 and a temperature of from about 20-25° C.5. The peptide-albumin hydrogel of claim 1 , wherein the weight ratio of peptide to albumin is from about 100:1 to about 1:100.6. The peptide-albumin hydrogel of claim 1 , wherein said hydrophilic region is derived from a β-spiral motif of spider flagelliform silk protein claim 1 , and said hydrophobic and turning regions are derived from the third trans-membrane segment of subunit IV in the dihydropyridine sensitive human muscle L-type calcium channel.7. The peptide-albumin hydrogel of claim 1 , further comprising an active agent encapsulated in said 3-dimensional nanofiber matrix.8. The peptide-albumin ...

Подробнее
Номер записи: 19
29-01-2015 дата публикации

POLYURETHANE DISPERSIONS FOR SEALING THE TEATS OF THE MAMMARY GLANDS IN MILKING ANIMALS

Номер: US20150031542A1
Автор: Dörr Sebastian, Fraatz Kristine, Froyman Robrecht, Heckroth Heike, Hehnen Hans-Robert, Schoenberger Jan, Werling Hans-Otto
Принадлежит:

The present invention relates to aqueous polyurethane dispersions for sealing teats of animal mammary glands. 115-. (canceled)16. A method for sealing a teat of an animal mammary gland comprising applying a coating of a polyurethane dispersion to the teat of the animal mammary gland , wherein the polyurethane dispersion is obtained by preparing A1) organic polyisocyanates,', 'A2) polymeric polyols having number-average molecular weights of 400 to 8000 g/mol, and OH functionalities of 1.5 to 6, and', 'A3) optionally hydroxy-functional compounds having molecular weights of 62 to 399 g/mol, and also', 'A4) optionally isocyanate-reactive, anionic or potentially anionic and/or optionally nonionic hydrophilizing agents,, 'A) isocyanate-functional prepolymers from'}and B1) optionally with amino-functional compounds having molecular weights of 32 to 400 g/mol and', 'B2) with amino-functional, anionic or potentially anionic hydrophilizing agents, 'B) then reacting some or all of the free NCO groups of said prepolymers'}with chain extension, and dispersing the prepolymers in water before, during or after step B).18. The method of claim 16 , wherein the number-average particle size of the particles in the polyurethane dispersions claim 16 , as determined by means of laser correlation spectroscopy claim 16 , is less than 750 nm.19. The aqueous polyurethane dispersion of claim 16 , wherein the polyurethane dispersion has solids contents of 10% to 70% by weight claim 16 , based on the polyurethane contained therein.20. The aqueous polyurethane dispersion of claim 16 , wherein the polyurethane dispersion contains less than 5% by weight claim 16 , based on the total dispersion claim 16 , of unbound organic amines.21. The aqueous polyurethane dispersion of claim 16 , wherein there are no volatile amines and no ammonia in the polyurethane dispersion.22. The method of claim 16 , wherein in the polyurethane dispersion there is less than 2% by weight of organic solvents.23. The method ...

Подробнее
Номер записи: 20
24-04-2014 дата публикации

MATERIALS AND METHODS FOR REPAIR OF CARTILAGE DEFECTS

Номер: US20140114280A1
Автор: Long Marc
Принадлежит: ORTHOVITA, INC.

In one embodiment, the present invention includes a method for repairing a cartilage defect including: preparing a cartilage defect by removing unwanted or damaged tissue; creating at least one perforation into or through subchondral bone, below and/or adjacent to the cartilage defect to induce the flow of bone fluid; allowing the bone fluid to bleed through the at least one perforation up into the cartilage defect to fill at least a portion of the cartilage defect; and applying a biomaterial into the defect to produce a clot for cartilage regeneration. 1. A method for repairing a cartilage defect comprising:preparing a cartilage defect by removing unwanted or damaged tissue;creating at least one perforation into or through subchondral bone, below and/or adjacent to the cartilage defect to induce the flow of bone fluid;allowing the bone fluid to bleed through the at least one perforation up into the cartilage defect to fill at least a portion of the cartilage defect; andapplying a biomaterial into the defect to produce a clot for cartilage regeneration.2. The method of claim 1 , wherein the biomaterial is applied to the defect after bone fluid bleeds into the defect to fill at least a portion of the defect.3. The method of claim 2 , wherein a tourniquet is applied proximal to the cartilage defect prior to the step of preparing the cartilage defect claim 2 , and prior to the step of applying a biomaterial into the bleeding defect area claim 2 , the tourniquet is removed claim 2 , thereby allowing uninhibited bleeding up into the cartilage defect.4. The method of claim 1 , wherein the biomaterial includes a surgical hemostat.5. The method of claim 4 , wherein the surgical hemostat includes thrombin and collagen.6. The method of claim 1 , wherein the interaction of the biomaterial and the bone fluid forms an enhanced clot.7. The method of claim 6 , wherein the enhanced clot includes a matrix structure through which additional bone fluid migrates.8. The method of claim ...

Подробнее
Номер записи: 21
30-01-2020 дата публикации

METHODS OF MAKING FIBRIN COMPOSITIONS AND ARTICLES

Номер: US20200030486A1
Автор: "OHare Jonathan J.", Asmus Robert A., Bjork Jason W., Determan Amy S., NORTON Daniel V., Pekurovsky Mikhail L., PITERA Gino L.
Принадлежит:

A method of forming a fibrin hydrogel composition including providing one or more unitary masses of a fibrin hydrogel, dividing at least one of the unitary masses of the fibrin hydrogel into a multiplicity of smaller pieces of the fibrin hydrogel, and recombining at least a portion of the smaller pieces into a cohesive mass. Dividing at least one of the unitary masses of fibrin hydrogel into a multiplicity of smaller pieces may include shearing or cutting the unitary masses to form an aqueous dispersion of the fibrin hydrogel in an aqueous medium. The aqueous dispersion of fibrin hydrogel may be applied to a substrate on a roller or an endless belt, and is optionally overlaid by a scrim. The cohesive mass of fibrin hydrogel, which may be formed by removing at least a portion of the aqueous medium from the aqueous dispersion of the smaller pieces of the fibrin hydrogel, finds uses in wound dressing articles. 1. A method of forming a fibrin hydrogel composition comprisingproviding one or more unitary masses of a fibrin hydrogel comprising fibrin;dividing at least one of the unitary masses of the fibrin hydrogel into a plurality of smaller pieces of the fibrin hydrogel;recombining at least a portion of the smaller pieces into a cohesive mass, optionally wherein the cohesive mass is on a substrate.2. The method of claim 1 , wherein dividing at least one of the unitary masses of the fibrin hydrogel into a plurality of smaller pieces of the fibrin hydrogel comprises shearing the one or more unitary masses of the fibrin hydrogel to form an aqueous dispersion of the smaller pieces of the fibrin hydrogel in an aqueous medium.3. The method of claim 2 , further comprising adding an aqueous liquid to the one or more unitary masses of the fibrin hydrogel.4. The method of claim 1 , wherein the smaller pieces of the fibrin hydrogel exhibit a particle size of no greater than 5 mm.5. The method of claim 3 , wherein the one or more unitary masses of the fibrin hydrogel comprise a ...

Подробнее
Номер записи: 22
04-02-2021 дата публикации

Medical hydrogel comprising nanofibrillar cellulose, tailored wound dressing, and methods for preparing thereof

Номер: US20210030919A1
Автор: KOIVUNIEMI Raili, LUUKKO Kari, Nuopponen Markus, SNIRVI Jasmi, Yliperttula Marjo
Принадлежит:

A medical hydrogel includes nanofibrillar cellulose, wherein the content of nanofibrillar cellulose in the hydrogel is in the range of 1-3.5% (w/w), and the nanofibrillar cellulose includes anionic nanofibrillar cellulose having an average fibril diameter of 200 nm or less. The medical hydrogel can be used for inducing vascularization in wounds and/or for treating deep wounds of dermis and/or below tissue. 1. A method for preparing a mouldable medical hydrogel , the method comprisingproviding anionically modified pulp, such as wood pulp, orproviding pulp, such as wood pulp, and modifying the pulp anionically,disintegrating anionically modified the pulp until nanofibrillar cellulose having an average fibril diameter of 200 nm or less is obtained,homogenizing the disintegrated anionically modified pulp in one or more non-fibrillating homogenizing step,forming the nanofibrillar cellulose into a mouldable medical hydrogel having a content of nanofibrillar cellulose in the range of 2-3.5% (w/w), such as 2.5-3.5% (w/w), and having a viscosity in the range of 500-2200 Pa·s, such as in the range of 700-1800 Pa·s, measured with a viscometer at the concentration of the hydrogel and at 37° C. at a shear rate of 0.1 1/s.2. A mouldable medical hydrogel comprising nanofibrillar cellulose , wherein the content of nanofibrillar cellulose in the hydrogel is in the range of 2-3.5% (w/w) , and the nanofibrillar cellulose comprises anionic nanofibrillar cellulose having an average fibril diameter of 200 nm or less , wherein the hydrogel has a viscosity in the range of 500-2200 Pa·s measured with a viscometer at the concentration of the hydrogel and at 37° C. at a shear rate of 0.1 1/s.3. The mouldable medical hydrogel of claim 2 , wherein the content of nanofibrillar cellulose in the hydrogel is in the range of 2.5-3.5% (w/w).4. The mouldable medical hydrogel of claim 2 , wherein the hydrogel has a viscosity in the range of 700-1800 Pa·s claim 2 , measured with a viscometer at the ...

Подробнее
Номер записи: 23
08-02-2018 дата публикации

FLOWABLE HEMOSTATIC COMPOSITION

Номер: US20180036338A1
Автор: Barry John Joseph Anthony, Fulghum Timothy Michael, Sanders Paul Jefferey
Принадлежит:

The present disclosure relates, in general, to hemostatic compositions comprising polysaccharide based polymers, such as amylopectins, amylose, dextrins, maltodextrins and icodextrin and modified forms thereof, cross-linked with a cross-linking agent that are useful as a hemostatic composition. Also provided are methods of treating injury and slowing or stopping bleeding using a hemostatic composition disclosed herein. 1. A hemostatic composition comprising a cross-linked amylopectin , icodextrin or maltodextrin or a cross-linked modified amylopectin , icodextrin or maltodextrin , wherein the composition is a flowable hydrogel , the hemostatic composition further comprising a procoagulant.2. The hemostatic composition of claim 1 , further comprising one or more agents selected from the group consisting of a blood clotting factor claim 1 , a styptic claim 1 , an astringent claim 1 , and other hemostatic agent.3. The method of claim 1 , wherein the procoagulant is thrombin.4. The hemostatic composition of claim 1 , wherein amylopectin claim 1 , icodextrin or maltodextrin further comprises a functional group selected from the group consisting of an amine claim 1 , an aldehyde claim 1 , a phosphate claim 1 , a phosphonate claim 1 , a sulfate claim 1 , a sulfonate claim 1 , and a carboxylate group.5. The hemostatic composition of claim 1 , wherein the composition activates the coagulation cascade or enhances binding to tissues.6. The hemostatic composition of claim 1 , wherein the cross-linked amylopectin claim 1 , icodextrin or maltodextrin or cross-linked modified amylopectin claim 1 , icodextrin or maltodextrin comprises a crosslinking agent selected from the group consisting of epichlorohydrin claim 1 , bis-epoxypropylether claim 1 , ethylene glycol-bis-epoxy propyl ether claim 1 , sodium trimetaphosphate (STMP) claim 1 , adipic-acetic anhydride claim 1 , phosphorous oxychloride claim 1 , formaldehyde claim 1 , a diepoxide claim 1 , vinylcyclohexene dioxide claim 1 , ...

Подробнее
Номер записи: 24
06-02-2020 дата публикации

Fibrinogen composition, method and wound articles

Номер: US20200038546A1
Автор: Amy S. Determan, James P. DiZio, Jason W. Bjork, Jonathan J. O'hare, Robert A. Asmus, Zhicheng TIAN
Принадлежит: 3M Innovative Properties Co

Provided is a method of forming a fibrinogen hydrogel composition, the method including providing a fibrinogen hydrogel or precursor thereof, comprising fibrinogen hydrogel forming salt. The fibrinogen hydrogel forming salt concentration is greater than or equal to the threshold concentration to form a fibrinogen hydrogel. The method further includes denaturing the fibrinogen hydrogel such as by heating. The method optionally further includes combining the fibrinogen hydrogel with a carrier material. When present, the concentration of the carrier material typically ranges from 0.1 to about 50 wt.-%. The method further includes reducing the salt concentration below the threshold concentration to form a fibrinogen hydrogel.

Подробнее
Номер записи: 25
16-02-2017 дата публикации

Dry Spray on Hemostatic System

Номер: US20170043051A1
Автор: LAVIK Erin
Принадлежит:

The invention provides for dry spray compositions comprising co-polymers comprising a core, water-soluble polymer and a peptide. 1. A dry spray composition comprising a co-block polymer.2. The dry spray composition of wherein the co-block polymer is coupled with a water soluble polymer.3. The dry spray composition of wherein the co-block polymer is a nanoparticle comprising a core claim 1 , a water soluble polymer and a peptide.4. The dry spray composition of comprising a nanoparticle claim 1 , wherein the nanoparticle comprises a water soluble polymer attached to the core at a first terminus of the water soluble polymer.5. The dry spray composition of claim 3 , wherein the peptide comprises an RGD amino acid sequence.6. The dry spray composition of further comprising a polycation.78-. (canceled)9. The dry spray composition of claim 1 , wherein the co-block polymer is poly(lactide-co-glycolide acid (PLGA) claim 1 , polylactic acid (PLA) claim 1 , polyglycolide (PGA) claim 1 , polycaprolactone (PCL) claim 1 , poly (ε-caprolactone) claim 1 , poly-L-lysine (PLL) or combinations thereof.10. The spray composition of wherein the water soluble polymer is selected from the group consisting of polyethylene glycol (PEG) claim 2 , branched PEG claim 2 , polysialic acid (PSA) claim 2 , carbohydrate claim 2 , polysaccharides claim 2 , pullulane claim 2 , chitosan claim 2 , hyaluronic acid claim 2 , chondroitin sulfate claim 2 , dermatan sulfate claim 2 , starch claim 2 , dextran claim 2 , carboxymethyl-dextran claim 2 , polyalkylene oxide (PAO) claim 2 , polyalkylene glycol (PAG) claim 2 , polypropylene glycol (PPG) claim 2 , polyoxazoline claim 2 , poly acryloylmorpholine claim 2 , polyvinyl alcohol (PVA) claim 2 , polycarboxylate claim 2 , polyvinylpyrrolidone claim 2 , polyphosphazene claim 2 , polyoxazoline claim 2 , polyethylene-co-maleic acid anhydride claim 2 , polystyrene-co-maleic acid anhydride claim 2 , poly(1-hydroxymethylethylene hydroxymethylformal) (PHF) claim 2 , ...

Подробнее
Номер записи: 26
15-02-2018 дата публикации

FIBRIN COMPOSITION, METHOD AND WOUND ARTICLES

Номер: US20180043055A1
Автор: BAKER BRYAN A., BEEN RAHA A., Bjork Jason W., NINKOVIC Jana, Young Alexi J
Принадлежит:

A method of forming a fibrin hydrogel composition is described. The method comprises forming an aqueous solution comprising fibrinogen, fibrin-forming enzyme, and a fibrin hydrogel forming salt. The fibrin hydrogel forming salt concentration is greater than or equal to the threshold concentration to form a fibrin hydrogel. The method further comprises reducing the salt concentration below the threshold concentration to form a fibrin hydrogel. In some embodiments, the aqueous solution further comprises a plasticizer. A fibrin composition is also described comprising a fibrin hydrogel having a fibrin concentration ranging from 0.1 to 10 wt-%; and a fibrin hydrogel forming salt. The fibrin hydrogel forming salt has a concentration less than a threshold concentration to form the fibrin hydrogel. The fibrin hydrogel or dehydrated fibrin hydrogel can be in various physical forms such a sheet, foam, or plurality of pieces. Also described are methods of forming a fibrin article, wound dressings and a method of treatment of a wound. 1. A method of forming a fibrin hydrogel composition comprisingforming an aqueous solution comprising fibrinogen, fibrin-forming enzyme, and a fibrin hydrogel forming salt; wherein the fibrin hydrogel forming salt has a concentration greater than or equal to the threshold concentration to form a fibrin hydrogel;reducing the salt concentration below the threshold concentration to form a fibrin hydrogel.2. The method of wherein the fibrin hydrogel forming salt comprises calcium salt.3. The method of wherein the threshold concentration of the aqueous solution is at least 0.45 wt %.4. The method of wherein the aqueous solution further comprises a plasticizer.5. The method of wherein the plasticizer comprises a sugar alcohol claim 4 , an alkane diol claim 4 , or a combination thereof.6. The method of wherein the solution further comprises a buffering agent.7. The method of further comprising forming the fibrin hydrogel into a sheet claim 1 , foam ...

Подробнее
Номер записи: 27
03-03-2022 дата публикации

Lyophilized Cured Polymeric Foam Plug

Номер: US20220062497A1
Автор: DeAnglis Ashley, Dhanaraj Sridevi, Ghodbane Salim
Принадлежит:

The present invention is directed to dry lyophilized foam plugs that are a polymeric reaction product of at least a pair of co-reactive polyethylene glycol having reactive moieties in which substantially all of reactive moieties have reacted prior to lyophilization or blend of biomaterial and a reactive polyethylene glycol or plasma derived biomaterial reaction product and wherein the plug has an overall pore void content of about 30-45%, and a microporous structure with an average pore generally between 20 and 95 μm.

Подробнее
Номер записи: 28
14-02-2019 дата публикации

COMPOSITIONS AND METHODS FOR TREATING CHRONIC WOUNDS

Номер: US20190046547A1
Автор: Aslam Rummana
Принадлежит: Hackensack University Medical Center

The described invention provides pharmaceutical compositions and methods for treating chronic non-healing wounds. The pharmaceutical compositions of the described invention comprise a granulated sugar and a hydrogel biomaterial. 1. A method for treating a chronic non-healing wound in a subject , wherein the method comprises administering to the subject a pharmaceutical composition comprising granulated sugar and a hydrogel biomaterial , wherein the pharmaceutical composition is effective to increase average percent wound closure as compared to a control.2. The method according to claim 1 , wherein the average percent wound closure ranges from about 50% to about 100% as compared to the control.3. The method according to claim 2 , wherein the average percent wound closure is at least 50% greater than the control.4. The method according to claim 2 , wherein the average percent wound closure is at least 95% greater than the control.5. The method according to claim 2 , wherein the average percent wound closure is at least 99% greater than the control.6. The method according to claim 1 , wherein the control is a hydrogel biomaterial.7. The method according to claim 1 , wherein the hydrogel biomaterial comprises purified water claim 1 , glycerol claim 1 , hydroxyl ethyl cellulose claim 1 , sodium lactate and allantoin.8. The method according to claim 7 , wherein the purified water is about 70% of the hydrogel biomaterial and the glycerol is about 30% of the hydrogel biomaterial.9. The method according to claim 1 , wherein the pharmaceutical composition comprises equal parts (1:1 v/v) of the granulated sugar and the hydrogel biomaterial.10. The method according to claim 1 , wherein the pharmaceutical composition is administered topically.11. The method according to claim 1 , wherein the pharmaceutical composition is coated on at least one surface of a dressing.12. The method according to claim 11 , wherein the dressing comprises an occlusive dressing and a non-adherent pad ...

Подробнее
Номер записи: 29
14-02-2019 дата публикации

POLYMERIC COMPOSITIONS, DELIVERY DEVICES, AND METHODS

Номер: US20190046683A1
Автор: BARRY JOHN, Klunk Stephanie, Ko Ben, Parmar Krishnakumarsinh H., Sanders Paul, Singh Rahul
Принадлежит:

Polymeric compositions, methods, and delivery devices for inhibiting bleeding are disclosed. The method includes applying a dried material topically to a wound site, where the material may include a cross-linked biologically compatible polymer which forms a hydrogel when exposed to blood and where the material may not include an active agent such as thrombin. A spring-loaded delivery device as described herein may be used to apply the dried material. 1. A method for inhibiting bleeding , the method comprising: 'a biologically compatible polymer which forms a hydrogel when exposed to blood; and', 'applying a powdered or dried material topically to a wound site, the material comprisingwherein the material does not comprise an active agent.2. The method of claim 1 , wherein the hydrogel comprises dry claim 1 , cross-linked gelatin polymer particles.3. The method of claim 1 , wherein the biologically compatible polymer has a degradation time of at least one day.4. The method of claim 1 , wherein the biologically compatible polymer is sized and dimensioned such that the polymer forms the hydrogel with a sub-unit size in the range from 0.01 mm to 0.5 mm.5. The method of claim 1 , wherein the biologically compatible polymer has an equilibrium swell in the range from 30% to 1000%.6. The method of claim 1 , wherein the biologically compatible polymer is present at from 50 percent by weight to 100 percent by weight of the material.7. The method of claim 6 , wherein the material further comprises an additive present at from 1 percent by weight to 20 percent by weight of the material.8. The method of claim 7 , wherein the additive is selected from the group consisting of polyvinylpyrrolidone claim 7 , dextran claim 7 , polyethylene glycol claim 7 , sorbitol claim 7 , and glycerol.9. The method of claim 1 , wherein the biologically compatible polymer is a cross-linked protein selected from the group consisting of gelatins claim 1 , collagens claim 1 , albumin claim 1 , ...

Подробнее
Номер записи: 30
13-02-2020 дата публикации

FORMED SHEET PRODUCT AND HEMOSTATIC MATERIAL

Номер: US20200046877A1
Автор: Aklyama Yusuke, Fujinaga Kentaro, HIRASHIMA MASAKI, HONDA Susumu, Imamura Takayuki, Kageyama Yukako, Kaneko Hiroaki, Kawamura Ryoichi, OONO Akitoshi, Satake Makoto, YAMAGUCHI Ayuko
Принадлежит:

A formed sheet product of a polymer composition comprising at least one protein selected from the group consisting of fibrinogen and thrombin and at least one polymer selected from the group consisting of an aliphatic polyester and a water-soluble polymer, and a laminated formed sheet product comprising a first polymer composition layer composed of fibrinogen and a water-soluble polymer and a second polymer composition layer composed of thrombin and an aliphatic polyester are provided. These formed products are applied onto a wound site and function as a hemostatic material. 1. A formed sheet product of a polymer composition comprising at least one protein selected from the group consisting of fibrinogen and thrombin and at least one polymer selected from the group consisting of an aliphatic polyester and a water soluble polymer , wherein at least one part of said at least one protein is incorporated into and is not covalently bonded to said at least one polymer , andwherein the formed sheet product is manufactured from a suspension composed of a solution of the polymer and particles of the protein.2. The formed sheet product according to claim 1 , wherein the at least one polymer selected from the group consisting of an aliphatic polyester and a water-soluble polymer is selected from the group consisting of a cellulose derivative claim 1 , a polymer having an N-vinyl cyclic lactam unit claim 1 , polyethylene oxide claim 1 , polyvinyl alcohol claim 1 , hyaluronic acid claim 1 , dextran claim 1 , pullulan claim 1 , starch claim 1 , and a mixture thereof.3. The formed sheet product according to claim 1 , wherein the at least one polymer selected from the group consisting of an aliphatic polyester and a water-soluble polymer is selected from the group consisting of hydroxypropyl cellulose claim 1 , methyl cellulose claim 1 , hydroxyethyl cellulose claim 1 , hydroxypropylmethyl cellulose claim 1 , sodium carboxymethyl cellulose claim 1 , and a mixture thereof.4. The ...

Подробнее
Номер записи: 31
23-02-2017 дата публикации

REMOVABLE FILM FORMING GEL COMPOSITIONS AND METHODS FOR THEIR APPLICATION

Номер: US20170049926A1
Автор: Asmus Robert A., COLAK ATAN SEMRA, Griesgraber George W., Hays David S., Langer-Anderson Delony L., Pereira Junia M., Rasmussen Jerald K., Solberg Michael J., Wlaschin Katie F., Young Alexi J.
Принадлежит:

Film forming gel compositions, useful in creating conformable and flexible gel bandages, can be formulate from a film forming polymer, a tackifier, and a volatile solvent. The film forming gels can also include antiseptics, cationic polymer coagulants, fillers, and other additives. The gel compositions form relatively thick films when dried on tissue, and can exhibit enhanced breathability to promote wound healing. 2. The composition of claim 1 , wherein the film forming polymer is selected from the group consisting of polydiorganosiloxane polyurea claim 1 , polydiorganosiloxane polyamine claim 1 , polysiloxane carbonate claim 1 , polydiorganosiloxane polyamide claim 1 , and combinations thereof.3. The composition of claim 2 , wherein the film forming polymer is a polydiorganosiloxane polyamide.4. The composition of claim 3 , wherein the polydiorganosiloxane polyamide is a polydiorganosiloxane polyoxamide.5. The composition of claim 1 , wherein the cationic polymer comprises a guanidinyl-containing polymer.6. The composition of claim 5 , wherein the guanidinyl-containing polymer is an aminopolymer functionalized with one or more guanidinyl groups.7. The composition of claim 6 , wherein the guanidinyl-containing polymer is guanidinylated polyethyleneimine.8. The composition of claim 1 , wherein the Brookfield viscosity of the composition is at least 100 claim 1 ,000 cps and no greater than 500 claim 1 ,000 cps.9. The composition of claim 1 , wherein the volatile solvent is selected from the group consisting of isooctane claim 1 , hexamethyldisiloxane claim 1 , and combinations thereof.10. A film useful as a conformable bandage claim 1 , wherein the film exhibits an upright MVTR of at least 300 g/m/24 hours claim 1 , a Skin Adhesion of at least 50 g/inch and no greater than 900 g/inch claim 1 , an elongation of at least 100% claim 1 , and an ultimate tensile strength of at least 0.3 MPa claim 1 ,wherein at least a portion of the film has a thickness of at least 2 mils ...

Подробнее
Номер записи: 32
22-02-2018 дата публикации

COMPOSITION, ARTICLES AND METHODS FOR WOUND CARE

Номер: US20180050128A1
Автор: FLEMMENS Michael S., GABRIELE Peter D., HARRIS Jeremy J., ROBERTSON Jeffrey H., WROBLESKY Kayla
Принадлежит:

Delivery articles for wound and surgical site treatment to prevent adhesion, provide antimicrobial benefits, and provide tissue scaffolding or support. The articles include (1) a dispensing unit or similar apparatus, the dispensing unit being selected from a pressurized or pressurizable apparatus. The dispensing unit contains (2) (a) a PGS resin, optionally including micronized PGS thermoset resin (b) a solvent (c) optionally, a propellant or other dispersant, (d) optionally, a mixture or suspension or dispersion or solution of one or more biologic tissue engineering ECM-compatible biologic components, antimicrobials, drugs, growth enhancers, stimulants, trophic agents, tissues, tissue matrices, and cells, and (e) optionally, one or a combination of structural matrix materials, fibers and fillers, gelatin and collagen. 1. An article comprising(1) a dispenser selected from a pressurized and a pressurizable apparatus, and (a) at least one resin selected from PGSU resin, PGS resin selected from PGS and OGS, and other polyol/diacid resins, and', '(b) at least one solvent,, '(2) a composition comprising'}wherein the composition (2) is contained within the dispensing unit.2. An article according to claim 1 , wherein the resin has a molecular weight in the range of from about 1 claim 1 ,000 to about 50 claim 1 ,000 Da.3. An article according to claim 1 , comprising (c) at least one propellant or other dispersant.4. An article according to claim 1 , comprising (d) at least one biological active selected from biologic tissue engineering ECM-compatible biologic components claim 1 , antimicrobials claim 1 , drugs claim 1 , growth enhancers claim 1 , stimulants claim 1 , trophic agents claim 1 , tissues claim 1 , tissue matrices claim 1 , and cells.5. An article according to claim 1 , comprising (e) at least one of structural matrix materials claim 1 , fibers claim 1 , fillers claim 1 , gelatin and collagen.6. An article according to claim 5 , wherein (e) comprises a filler ...

Подробнее
Номер записи: 33
26-02-2015 дата публикации

GEL, IN PARTICULAR FOR USE IN A WOUND TREATMENT AGENT

Номер: US20150056304A1
Автор: Mathé Hans-Georg
Принадлежит:

A gel, in particular for use in a wound treatment agent includes an inorganic silicate as thickener; and an electrochemically activated aqueous common salt solution having a content of free chlorine of more than 200 mg/l and a conductivity of not more than 12 mS/cm. 113.-. (canceled)14. A gel , comprising:an inorganic silicate as thickener; andan electrochemically activated aqueous common salt solution having a content of free chlorine of more than 200 mg/l and a conductivity of not more than 12 mS/cm.15. The gel of claim 14 , for use in a wound treatment agent.16. The gel of claim 14 , wherein the electrochemically activated aqueous common salt solution is obtained by mixing an electrochemically activated starting common salt solution having a content of free chlorine of more than 300 mg/l with distilled water.17. The gel of claim 14 , wherein a mixture ratio of thickener/common salt solution is between about 3 and about 5% by weight.18. The gel of claim 16 , wherein the starting common salt solution has a content of free chlorine of more than 500 mg/l claim 16 , preferably of more than 600 mg/l.19. The gel of claim 16 , wherein the starting common salt solution has a redox potential of between 600 and 1000 mV claim 16 , preferably between 700 and 900 mV claim 16 , particularly preferably of about 800 mV.20. The gel of claim 16 , wherein the starting common salt solution has a conductivity of between 12 and 16 mS/cm.21. The gel of claim 16 , wherein the starting common salt solution has a pH value of between 6 and 8 claim 16 , preferably of about 7.22. The gel of claim 14 , wherein the common salt solution has a conductivity of between 10 and 12 mS/cm claim 14 , preferably of about 11 mS/cm.23. The gel of claim 14 , wherein the thickener is a lithium-magnesium-sodium silicate.24. The gel of claim 14 , wherein the thickener is a silicate from the montmorillonite group.25. The gel of claim 14 , wherein the thickener is Lucentite SWN.26. The gel of claim 14 , having a ...

Подробнее
Номер записи: 34
26-02-2015 дата публикации

Methods for Surgical Wound Dressing Incorporating Connected Hydrogel Beads Having an Embedded Electrode Therein

Номер: US20150057735A1
Автор: Malhi Arnaz
Принадлежит:

According to an embodiment of the present disclosure, a wound dressing system is presented. The wound dressing system includes a fluid permeable support layer, the support layer configured for positioning within a wound and adapted to generally conform to a topography of the wound, and to permit exudates from the wound to pass therethrough. The wound dressing system further includes a plurality of beads supported by the support layer, the beads defining an insulated inter-connected elongate member and an electrode embedded within and extending through at least a portion of the elongate member. Also, a current is generated by an external energy source that electrically flows through the electrode. 114-. (canceled)15. A method of manufacturing a wound dressing , the method comprising the steps of:providing a cover layer, wherein the cover layer is configured for positioning across a wound and is configured to permit exudates from the wound to pass therethrough;providing an elongate member positionable in the wound with adjacent beads connected to each other by connecting segments, the beads and the connecting segments comprising a hydrogel material; andproviding an electrode extending through at least some of the beads and through the connecting segments along a length of the elongate member;wherein a current generated by an energy source electrically flows through the electrode.16. The method according to claim 15 , further comprising providing a conduit for supplying reduced pressure to the wound.17. (canceled)18. The method according to claim 15 , wherein the electrode extends through an entire length of the elongate member.19. The method according to claim 15 ,wherein each bead of the plurality of beads has a first length;wherein adjacent beads of the plurality of beads are separated from each other by a second length; andwherein the first length is greater than the second length.20. The method according to claim 15 , wherein a portion of at least one bead of the ...

Подробнее
Номер записи: 35
17-03-2022 дата публикации

Hemostatic Powder Delivery Devices and Methods

Номер: US20220080132A1
Автор: Goodman John, Kiturkes Alex W., Schneider Jared
Принадлежит:

The present invention is directed to a device for the expression of a hemostatic powder having an elongated reservoir with a manual air pump, such as a bellows, at a proximal end and an expression port at a distal end. A porous filter is slidably disposed within the reservoir between the bellows and plunger and the expression port, and a spring is disposed within the reservoir between the air pump and the plunger. The powder is disposed within the reservoir between the porous filter and the expression port, and the pump is in a fluid communication with the expression port through the porous filter and through the powder. 2. The device of claim 1 , wherein said manual air pump comprises a bellows.3. The device of claim 1 , wherein said filter comprises interconnected pores or channels having size substantially preventing the powder from passing through the filter.4. The device of claim 1 , wherein said porous filter is attached to a plunger slidably disposed within the reservoir between said filter and said manual air pump and a hollow expression cannula is attached to said expression port and extends from the device distally claim 1 , said expression cannula is in fluid communication with said pump.5. The device of claim 4 , wherein said plunger has an elongated stem extending from said plunger towards the proximal end and said spring is at least partially supported on said stem.6. The device of claim 4 , further comprisinga) a powder trap positioned between the expression port and the expression cannula, the powder trap comprisingi) a tortuous channel for the powder, the channel having an entrance orifice open to the reservoir and an exit opening open to the expression cannula.7. The device of claim 6 , further comprising a blocking member within the reservoir claim 6 , wherein said powder trap is rotatable about the reservoir from a first position to a second position and in the first position the entrance orifice is blocked by the blocking member and in the ...

Подробнее
Номер записи: 36
10-03-2016 дата публикации

MICRONIZED PLACENTAL TISSUE COMPOSITIONS WITH OPTIONAL SEALANT AND METHODS OF MAKING AND USING THE SAME

Номер: US20160067287A1
Автор: Burrows Frank, Koob Thomas, McQueen Adam
Принадлежит:

Described herein are compositions composed of micronized placental components and optionally a sealant, and pharmaceutical compositions thereof. Also described are systems, apparatuses, and methods for applying the combination of micronized placental components and adhesives optionally a sealant (e.g., adhesive or gelation agent) for wound care and other medical applications. 1. A composition comprising micronized placental tissue selected from the group consisting of amnion , chorion , intermediate tissue layer , or any combination thereof and a biocompatible adhesive or biocompatible gelation agent in a suitable excipient , wherein the composition is in a flowable form prior to application to a subject.2. The composition of claim 1 , wherein the composition is a liquid claim 1 , a gel claim 1 , or a paste prior to application.3. The composition of claim 1 , wherein the composition becomes a solid claim 1 , a semi-solid claim 1 , or a gel after application to a subject.4. The composition of claim 1 , wherein the biocompatible gelation agent comprises a thermosensitive sol-gel reversible hydrogel.5. The composition of claim 4 , wherein the biocompatible gelation agent is a poloxamer.6. The composition of claim 1 , wherein the biocompatible adhesive is selected from the group consisting of: polyacrylate claim 1 , polyisobutylene claim 1 , a methylidene malonate polymer claim 1 , and a cyanoacrylate.7. The composition of claim 1 , wherein the micronized placental tissue and the biocompatible adhesive or gelation agent are mixed immediately prior to application to the wound.8. The composition of claim 1 , wherein the micronized placental tissue has a particle size of less than 100 μm.9. The composition of which is a topical composition.10. The composition of which is a sprayable composition.11. A system for dressing a wound claim 1 , the system comprising:a first composition comprising micronized placental tissue selected from the group consisting of amnion, chorion, ...

Подробнее
Номер записи: 37
27-02-2020 дата публикации

MICRONIZED PLACENTAL TISSUE COMPOSITIONS WITH OPTIONAL SEALANT AND METHODS OF MAKING AND USING THE SAME

Номер: US20200061122A1
Автор: Burrows Frank, Koob Thomas, McQueen Adam
Принадлежит:

Described herein are compositions composed of micronized placental components and optionally a sealant, and pharmaceutical compositions thereof. Also described are systems, apparatuses, and methods for applying the combination of micronized placental components and adhesives optionally a sealant (e.g., adhesive or gelation agent) for wound care and other medical applications. 1. A composition comprising micronized placental tissue selected from the group consisting of amnion , chorion , intermediate tissue layer , or any combination thereof and a biocompatible adhesive or biocompatible gelation agent in a suitable excipient , wherein the composition is in a flowable form prior to application to a subject.2. The composition of claim 1 , wherein the composition is a liquid claim 1 , a gel claim 1 , or a paste prior to application.3. The composition of claim 1 , wherein the composition becomes a solid claim 1 , a semi-solid claim 1 , or a gel after application to a subject.4. The composition of claim 1 , wherein the biocompatible gelation agent comprises a thermosensitive sol-gel reversible hydrogel.5. The composition of claim 4 , wherein the biocompatible gelation agent is a poloxamer.6. The composition of claim 1 , wherein the biocompatible adhesive is selected from the group consisting of: polyacrylate claim 1 , polyisobutylene claim 1 , a methylidene malonate polymer claim 1 , and a cyanoacrylate.7. The composition of claim 1 , wherein the micronized placental tissue and the biocompatible adhesive or gelation agent are mixed immediately prior to application to the wound.8. The composition of claim 1 , wherein the micronized placental tissue has a particle size of less than 100 μm.9. The composition of which is a topical composition.10. The composition of which is a sprayable composition.11. A system for dressing a wound claim 1 , the system comprising:a first composition comprising micronized placental tissue selected from the group consisting of amnion, chorion, ...

Подробнее
Номер записи: 38
27-02-2020 дата публикации

Hemostatic Powder Delivery Devices and Methods

Номер: US20200061310A1
Автор: Goodman John, Kiturkes Alex W., Schneider Jared
Принадлежит:

The present invention is directed to a device for the expression of a hemostatic powder having an elongated reservoir with a manual air pump, such as a bellows, at a proximal end and an expression port at a distal end. A porous filter is slidably disposed within the reservoir between the bellows and plunger and the expression port, and a spring is disposed within the reservoir between the air pump and the plunger. The powder is disposed within the reservoir between the porous filter and the expression port, and the pump is in a fluid communication with the expression port through the porous filter and through the powder. 2. The device of claim 1 , wherein said manual air pump comprises a bellows.3. The device of claim 1 , wherein said filter comprises interconnected pores or channels having size substantially preventing the powder from passing through the filter.4. The device of claim 1 , wherein said porous filter is attached to a plunger slidably disposed within the reservoir between said filter and said manual air pump and a hollow expression cannula is attached to said expression port and extends from the device distally claim 1 , said expression cannula is in fluid communication with said pump.5. The device of claim 4 , wherein said plunger has an elongated stem extending from said plunger towards the proximal end and said spring is at least partially supported on said stem.6. The device of claim 4 , further comprising 'i) a tortuous channel for the powder, the channel having an entrance orifice open to the reservoir and an exit opening open to the expression cannula.', 'a) a powder trap positioned between the expression port and the expression cannula, the powder trap comprising'}7. The device of claim 6 , further comprising a blocking member within the reservoir claim 6 , wherein said powder trap is rotatable about the reservoir from a first position to a second position and in the first position the entrance orifice is blocked by the blocking member and in ...

Подробнее
Номер записи: 39
17-03-2016 дата публикации

OPTIMAL INTERSTRAND BRIDGE FOR COLLAGEN MIMICS

Номер: US20160075764A1
Автор: RAINES Ronald T., Tanrikulu Ismet C.
Принадлежит:

Novel collagen-mimetic peptides are disclosed comprising the formula (Xaa-Yaa-Gly), where the amino acid at one of the Xaa positions is substituted with a homocysteine residue. Also disclosed are multi-stranded novel collagen-mimetic peptides comprising a first strand as described above that is covalently bonded with a disulfide bridge to a second strand comprising the formula (Xaa-Yaa-Gly), where the amino acid at one of the Yaa positions is substituted with a cysteine residue. Disulfide formation between the terminal thiol sulfur of the homocysteine residue of the first strand and the terminal thiol sulfur of the cysteine residue of the second strand reveals unstrained bridges that enhance the structure and substantially improve the stability of collagen triple helices as compared to other possible disulfide or thioether bridges. Thus, the disclosed collagen mimetic peptides have improved stability, and can be used to produce optimized collagen-like fibrillar assemblies for wound healing and other biomedical applications. 1. A collagen-mimetic peptide comprising the formula (Xaa-Yaa-Gly)-Hcy-Yaa-Gly-(Xaa-Yaa-Gly) , wherein Gly is glycine , Hcy is homocysteine , each Xaa and each Yaa is independently any amino acid residue , and n and m are independently zero or any positive integer.2. The collagen-mimetic peptide of claim 1 , wherein each Xaa and each Yaa is independently selected from the group consisting of proline claim 1 , hydroxyproline claim 1 , and an amino acid residue having a side chain capable of being functionalized.3. The collagen-mimetic peptide of claim 1 , wherein each Xaa is proline and each Yaa is hydroxyproline or proline.4. The collagen-mimetic peptide of claim 1 , wherein n is an integer from 0 to 16 claim 1 , m is an integer from 0 to 16 claim 1 , and the sum of n+m is from 0 to 16.5. The collagen-mimetic peptide of claim 1 , wherein the collagen-mimetic peptide consists essentially of the formula (Xaa-Yaa-Gly)-Hcy-Yaa-Gly-(Xaa-Yaa-Gly) claim ...

Подробнее
Номер записи: 40
19-03-2015 дата публикации

Pharmaceutical composition for repairing wound and/or regenerating tissue, method and uses thereof

Номер: US20150079067A1
Автор: TSAI Hsin-Chung
Принадлежит: Taichung Hospital, Ministry of Health and Welfare

This invention discloses a method to produce a pharmaceutical composition from bloods for repairing wound which don't have to extra add commercial thrombins or non-human thrombins but to manufacture the pharmaceutical composition from bloods for repairing wound directly from bloods. Therefore, the method discloses in this present invention have the effect to avoid the rejection reaction of the treated patients and to reduce the costs of production, and furthermore to decrease medical costs and the burden of patients. 1. A method to manufacture a pharmaceutical composition from bloods for repairing wound and/or regenerating tissue , including following steps:a. providing at least two tubes of blood, wherein one tube of blood is without the anticoagulant and the other one tube of blood contains the anticoagulant;b. collecting an upper layer from the tube of blood without the anticoagulant after centrifuging;c. centrifuging the other one tube of blood containing the anticoagulant divided into at least three layers, wherein the first layer contains erythrocytes, the second layer contains platelet-rich plasma and the third layer contains platelet-poor plasma;d. collecting the platelet-rich plasma from the three layers of the step c.;e. collecting the platelet-poor plasma from three layers of the step c.; andf. mixing some of the upper layer from the step b., the platelet-rich plasma from the step d., the platelet-poor plasma from the step e. and calcium with a predetermined ratio to have a pharmaceutical composition for repairing wound.2. The method according to claim 1 , wherein the step b. is further separated the upper layer into a mantle consisting of platelet-rich fibrin and a liquid object consisting of thrombin.3. The method according to claim 2 , wherein the step f. is to mix the liquid object claim 2 , the platelet-rich plasma from the step d. claim 2 , the platelet-poor plasma from the step e. and calcium with a predetermined ratio.4. The method according to ...

Подробнее
Номер записи: 41
05-06-2014 дата публикации

COMPOSITION CONTAINING A CELLULOSE, A VEGETABLE OIL AND A VOLATILE SOLVENT, AND USE THREOF AS A DRESSING

Номер: US20140154188A1
Автор: Derain Nathalie
Принадлежит: LABORATOIRES URGO

The present invention relates to a composition in the fluid form intended to form a dressing on the skin. This composition comprises from 6% to 12% by weight of the total weight of the composition of a cellulose derivative, from 5% to 15% by weight of the total weight of the composition of a vegetable oil, and a volatile solvent. The oil/cellulose ratio by weight is between 0.8 and 1.5. 1. A fluid composition intended to be applied to the skin , comprising a cellulose derivative , a vegetable oil and a solvent for said derivative which is volatile , wherein the cellulose derivative represents from 6% to 13% by dry weight of the total weight of the composition , wherein the vegetable oil represents from 5% to 15% by weight of the total weight of the composition and wherein the oil/cellulose ratio by weight , by dry weight , is between 0.8 and 1.5.2. The composition as claimed in claim 1 , wherein the cellulose derivative is a nitrocellulose.3. The composition as claimed in claim 1 , wherein the vegetable oil is castor oil.4. The composition as claimed in claim 1 , wherein the oil represents between 7% and 12% by weight of the total weight of the composition.5. The composition as claimed in claim 1 , wherein the solvent for said cellulose derivative represents between 70% and 90% by weight of the total weight of the composition.6. The composition as claimed in claim 1 , wherein the solvent for said cellulose derivative is chosen from ethanol claim 1 , ethyl acetate and their mixtures.7. The composition as claimed in claim 1 , which comprises nitrocellulose claim 1 , castor oil claim 1 , ethyl acetate and ethanol.8. The composition as claimed in claim 1 , which additionally comprises an ingredient chosen from depigmenting agents claim 1 , antibacterial agents claim 1 , antifungal agents claim 1 , healing agents claim 1 , pain killers claim 1 , anti-inflammatories claim 1 , hydrating agents claim 1 , keratolytic agents claim 1 , vitamins claim 1 , restructuring agents ...

Подробнее
Номер записи: 42
14-03-2019 дата публикации

KITS, COMPOSITIONS AND METHODS FOR WOUND TREATMENT AND MANAGEMENT

Номер: US20190076572A1
Автор: Saber Shien-Lin
Принадлежит:

The inventive subject matter provides compositions and methods for transiently or permanently treating or managing an injury. Contemplated compositions are polymerizable in situ over short time periods, even in the presence of blood, without undue exothermic heat. Contemplated compositions may further comprise an anesthetic, an antiseptic, an adhesion promoter, and/or a vasoconstrictor. 1. A method for transiently treating an injury wherein at least one of blood and tissue is exposed , comprising:at least partially filling the injury with a polymerizable composition, wherein the polymerizable composition polymerizes in the presence of the at least one of the blood and the tissue to form an elastic seal; andwherein the seal is removable for subsequent treatment of the injury.2. The method of claim 1 , wherein the polymerizable composition is flowable and applied to infuse between 0.25 mm-5 mm into tissue and blood vessels surrounding the injury.3. The method of claim 1 , further comprising applying a base component to the injury prior to at least partially filling the injury with the polymerizable composition claim 1 , wherein the base component comprises at least one of an anesthetic claim 1 , an antiseptic claim 1 , an adhesion promoter claim 1 , a catalyst that accelerates polymerization of the polymerizable composition claim 1 , and a vasoconstrictor.4. The method of claim 1 , wherein the polymerizable composition comprises a silicone mixture.5. The method of claim 4 , wherein the silicone mixture comprises: a first silicone elastomer component comprising a first platinum catalyst; and a second silicone elastomer component comprising a silicone crosslinker.6. The method of claim 5 , further comprising applying a base component to the injury prior to at least partially filling the injury with the silicone mixture claim 5 , wherein the base component comprises at least one of an anesthetic claim 5 , an antiseptic claim 5 , an adhesion promoter claim 5 , a catalyst ...

Подробнее
Номер записи: 43
23-03-2017 дата публикации

PHASE-SHIFTING FORMULATIONS

Номер: US20170080120A1
Автор: DE ZIEGLER Donimique, Levine Howard L.
Принадлежит: ULSTRAST, INC.

The inventive composition first is highly viscous, remaining in place when administered to a patient. Then it decreases in viscosity and liquefies, facilitating easy removal, after a period of time ranging from minutes to weeks, such as after a change in temperature or other trigger; or after another component is added to cause liquefaction. Such compositions have many different medical uses, optionally with a treating agent contained in, or held in place by, the composition, such as, without limitation, prevention or reduction in scarring or adhesions after surgery involving the uterus or other body or organ cavities or other sites, by keeping raw areas of the tissue or tissue walls separated from each other during healing; delivery or retention of treating agents in body or organ cavities or other sites of administration; protection of wounds, burns, and other injuries; and holding tissue grafts in place. Even cosmetic uses are available. 1. A phase-shifting formulation for avoiding post-surgical scarring and other adhesions , comprising a suitable gel or semi-solid component in a composition that is placed on a post-surgical tissue surface before , during , or after a surgical procedure , and keeps local tissues separated while allowing healing , and then is modified to facilitate removal from the surgical site.2. (canceled)3. The formulation of wherein the formulation is removed by use of a trigger that causes the formulation to lose its integrity to facilitate removal from the body cavity or tissue surface.4. (canceled)5. (canceled)6. The formulation according to wherein the formulation also delivers or maintains a treating agent or tissue regeneration stimulating agent to or on the tissue to promote healing and/or regeneration.7. (canceled)8. (canceled)9. A method of preventing or minimizing post-surgical scarring or other adhesions at a site that needs to heal post surgery claim 1 , comprising: preparing a viscosity-shifting composition for use during or ...

Подробнее
Номер записи: 44
31-03-2022 дата публикации

WOUND HEALING THERAPEUTIC HYDROGELS

Номер: US20220096709A1
Автор: Katyal Priya, Kuhn Joseph, Meleties Michael, Montclare Jin Kim, Rabbani Piul, Troncoso Juan Francisco Cortes
Принадлежит:

Provided are hydrogel-based compositions and materials for wound healing and methods of using same. The hydrogel comprises nanofibers formed from protein Q, which is a variant of the cartilage oligomeric matrix protein coiled coil (COMPcc) protein, or a protein having at least 85% homology with protein Q. The hydrogel has one or more wound healing agents distributed therein and associated with the Q fibers. The wound healing agent may be exosomes, which may be exosomes produced by cells, such as exosomes produced by multipotent stromal cells and/or one or more triterpenoids. The hydrogels may be used in treatment of wounds, such as chronic wounds. 1. A composition for wound healing comprising a hydrogel having distributed therein one or more wound healing agents , wherein the hydrogel comprises nanofibers comprising a protein having a sequence of SEQ ID NO:1 , SEQ ID NO:2 , a protein having 85% homology of SEQ ID NO:1 or SEQ ID NO:2 , or a combination thereof.2. The composition of claim 1 , wherein the wound healing agent is exosomes produced by human multipotent stromal cells.3. The composition of claim 2 , wherein the exosomes are obtained from the conditioned medium of a culture of multipotent stromal cell.4. The composition of claim 3 , wherein the multipotent stromal cells are obtained from bone marrow.5. The composition of claim 1 , wherein the hydrogel comprises 85 to 95 weight percent of water.6. The composition of claim 1 , wherein nanofibers have a concentration of 1 mM to 5 mM. The composition of claim 1 , wherein the nanofiber concentration is 2 mM.87. The composition of claim claim 1 , wherein the protein has the sequence of SEQ ID NO:1.97. The composition of claim claim 1 , wherein the protein has the sequence of SEQ ID NO:2.10. The composition of claim 1 , wherein the concentration of exosomes is 1×10to 1×10per ml of the hydrogel.11. The composition of claim 10 , wherein the concentration of exosomes is 5×10to 15×10per mL of the hydrogel.12. The ...

Подробнее
Номер записи: 45
25-03-2021 дата публикации

HYDROCOLLOID COMPOSITION AND BIO-PATCH CONTAINING THE SAME

Номер: US20210085822A1
Автор: Kim Tae Won
Принадлежит: HYU(INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY

Hydrocolloid composition and bio-patch comprising the same are provided. The hydrocolloid composition has a hydrophobic elastomer matrix. Hydrocolloid particles and aerogel particles are dispersed in the matrix. The aerogel particles may be silica aerogel particles. The aerogel particles may include particles having hydrophobic functional groups formed on the particle surface. The aerogel particles may be hydrophobic aerogel particles, hybrid aerogel particles in which hydrophobic functional groups and hydrophilic functional groups are simultaneously formed on the particle surface, or a mixture of the hydrophobic aerogel particles, the hybrid aerogel particles, and hydrophilic aerogel particles. 1. A hydrocolloid composition comprising:a hydrophobic elastomer matrix; andhydrocolloid particles and aerogel particles dispersed in the matrix.2. The hydrocolloid composition according to claim 1 , wherein the hydrocolloid composition contains 100 parts by weight of the hydrophobic elastomer claim 1 , 70 to 150 parts by weight of the hydrocolloid particles claim 1 , and 1 to 15 parts by weight of the aerogel particles.3. The hydrocolloid composition according to claim 1 , wherein the hydrophobic elastomer is a styrene-isoprene-styrene triblock copolymer (SIS).4. The hydrocolloid composition according to claim 1 , wherein the hydrocolloid particles are alginate crosslinked by calcium ions.5. The hydrocolloid composition according to claim 1 , wherein the aerogel particles are silica aerogel particles.6. The hydrocolloid composition according to claim 1 , wherein the aerogel particles have particles with hydrophobic functional groups formed on the particle surface.7. The hydrocolloid composition according to claim 6 , wherein the aerogel particles are hydrophobic aerogel particles claim 6 , hybrid aerogel particles in which hydrophobic functional groups and hydrophilic functional groups are simultaneously formed on the particle surface claim 6 , or a mixture of the ...

Подробнее
Номер записи: 46
25-03-2021 дата публикации

METHODS OF MAKING CHITOSAN/HYALURONIC ACID HYDROGEL COMPOSITIONS AND COMPOSITIONS MADE THEREFROM

Номер: US20210085823A1
Автор: EBESU Joanne S.M., Pollock Jacob, POON Dexter
Принадлежит:

A novel hydrogel wound dressing therapy and methods for making the same. The novel methods comprise forming two biopolymers, chitosan and hyaluronic acid, together into a wound dressing with inherent ability to enhance wound closure. The novel composition of the subject invention comprises cross-linked chitosan/hyaluronic acid hydrogels manufactured according to the methods disclosed having a specific cross-link density that results in a swelling ratio of 20 to 100. Hydrogels manufactured in accordance with the method of the invention dramatically increase healing rates and greatly improves outcomes of wound injuries. 1. A hydrogel preparation method , comprising:creating a chitosan suspension in water;adjusting pH of the chitosan suspension to between 4.7 and 7.5 to dissolve the chitosan and form a chitosan solution;combining first buffer salts with the chitosan solution;combining hyaluronic acid (HA) and second buffer salts in water and creating an HA solution with a pH of between 4.5 and 6.5;adding carbodiimide coupling and activating reagents to the HA solution, thereby creating an activated HA solution;adding the chitosan solution to the activated HA solution to form a resulting mixture; andallowing the resulting mixture to set to form a hydrogel.2. (canceled)3. (canceled)4. A hydrogel preparation method according to claim 1 , wherein the first and second buffer salts comprise a non-coordinating buffer salt and sodium chloride.5. A hydrogel preparation method according to claim 1 , wherein the first and second buffer salts comprise 2-(N-morpholino) ethanesulfonic acid (MES) containing sodium chloride.6. A hydrogel preparation method according to claim 5 , wherein the MES containing sodium chloride comprises between 0.05M and 5M MES and between 0.1% and 20% wt/vol NaCl in the chitosan and HA solutions.7. A hydrogel preparation method according to claim 5 , wherein the MES containing sodium chloride comprises 0.5M MES and 4% NaCl in the chitosan solution and 1M ...

Подробнее
Номер записи: 47
31-03-2016 дата публикации

Transdermal Delivery System

Номер: US20160089473A1
Автор: Boote Nicholas David, Munro Hugh Semple, Stewart Joanne Ellen, Tucker Arthur Tudor, Wood Christopher Barry
Принадлежит:

The present invention provides a system comprising: (i) a layer containing a nitrite; and (ii) a hydrogel that contains hydrogen ions; wherein the layer containing a nitrite and/or the hydrogel comprises a pharmaceutically active agent. The invention also provides the use of a system of the invention in medicine, and in the treatment of pain. 2. The system according to claim 1 , wherein the layer is a dissolvable film.3. The system according to claim 2 , wherein the dissolvable film is formed of a polyvinyl alcohol claim 2 , polyvinylpyrrolidone claim 2 , a cellulose-based polymer or cellulose.4. The system according to claim 1 , wherein the layer is a mesh.5. The system according to claim 4 , wherein the mesh is formed of a polymer.6. The system according to claim 5 , wherein the polymer is polypropylene.7. The system according to claim 1 , wherein the nitrite is an alkaline metal nitrite or an alkaline earth metal nitrite.8. The system according to claim 7 , wherein the nitrite is sodium nitrite.9. The system according to claim 1 , wherein the system comprises a plurality of layers containing a nitrite.10. The system according to claim 1 , wherein the nitrite is present as a nitrite solution.11. The system according to claim 1 , wherein the hydrogel is partially hydrated.12. The system according to claim 1 , wherein the hydrogel is cross-linked.13. The system according to claim 1 , wherein the hydrogel is a co-polymer.14. The system according to claim 13 , wherein the hydrogel is a co-polymer of polysulfonate and acrylic acid.15. The system according to claim 1 , wherein the system does not contain a thiol or a reductant.16. (canceled)17. The system according to claim 1 , wherein the pharmaceutically active agent is an anaesthetic selected from the group consisting of lignocaine (lidocaine) claim 1 , amethocaine (tetracaine) claim 1 , xylocaine claim 1 , bupivacaine claim 1 , prilocaine claim 1 , ropivacaine claim 1 , benzocaine claim 1 , mepivocaine claim 1 , ...

Подробнее
Номер записи: 48
05-05-2022 дата публикации

HYDROGEL COMPOSITION WITH THERMOS-SENSITIVE AND IONIC REVERSIBLE PROPERTIES, CARRIER, METHOD FOR PREPARING AND METHOD OF USE THEREOF

Номер: US20220135748A1
Автор: CHOU Hsiao-Ying, LIN Shuian-Yin, TSAI Hsieh-Chih
Принадлежит:

The present disclosure provides a method for preparing a hydrogel composition with thermos-sensitive and ionic reversible properties and the hydrogel composition prepared by the method. Related application products of the hydrogel composition of the present disclosure include wound dressings, drug carriers, three-dimensional cellular scaffolds, soluble microspheres, and cell capture and release systems, wherein the hydrogel composition with thermos-sensitive and ionic reversible properties has good in vitro and in vivo stability and high biocompatibility, and is non-toxic. The hydrogel composition can be removed and replaced by washing with metal chelating aqueous solution at low temperature.

Подробнее
Номер записи: 49
05-05-2022 дата публикации

SURGICAL HYDROGEL

Номер: US20220135750A1
Автор: Ghosh Smita, Robinson Simon Rae
Принадлежит:

Disclosed are surgical hydrogels derived from the combination of chitosan derivative and aldehyde-derivatised dextran polymers in combination with a humectant for use as surgical wound packing materials or stents. Also disclosed are sterile kits comprising the precursor components of the surgical hydrogels. Also disclosed are methods of sterilizing the kits and individual components thereof for preparing the hydrogels.

Подробнее
Номер записи: 50
01-04-2021 дата публикации

LIQUID BAND-AID CONTAINING PEPTIDE ANTI-INFLAMMATORY ACTIVE INGREDIENT AND PREPARATION METHOD THEREOF

Номер: US20210093748A1
Автор: GAO Peng, HUANG JU, Luo Hongyu, WANG ZHIGAO, YI CHONG, Yu Xinwei
Принадлежит:

The present invention provides a liquid band-aid containing peptide anti-inflammatory active ingredient and a preparation method thereof, which belong to the technical field of medical materials. The liquid band-aid includes film-forming agent, plasticizer, anti-inflammatory substance, and solvent, where the plasticizer includes glycerin, the solvent includes deionized water, and the anti-inflammatory substance includes high F-value oligopeptide with an amino acid sequence of Leu-Leu-Phe-Thr-Thr-Gln and a molecular weight of 736.52 Da. The liquid band-aid can promote the expression of interleukin 10 (IL-10) and inhibit the expressions of cytokine interleukin 6 (IL-6) and tumor necrosis factor (TNF-α), and thus have good anti-inflammatory activity. The liquid band-aid further enhances the close contact between gel and an injured skin surface, increases the cleanliness of a wound surface, and improves the clearance rate of inflammatory cells. 1. A liquid band-aid containing peptide anti-inflammatory active ingredient , comprising film-forming agent , plasticizer , anti-inflammatory substance and solvent , wherein the plasticizer comprises glycerin , the solvent comprises deionized water , the anti-inflammatory substance comprises high F-value oligopeptide with an amino acid sequence of Leu-Leu-Phe-Thr-Thr-Gln (SEQ ID NO.1) and a molecular weight of 736.52 Da.2. The liquid band-aid according to claim 1 , wherein the film-forming agent comprises polyvinyl alcohol and modified chitosan.3. The liquid band-aid according to claim 2 , wherein the modified chitosan is hydroxycinnamic acid modified chitosan claim 2 , and dihydroxycoumarin is grafted on the hydroxycinnamic acid modified chitosan.4. The liquid band-aid according to claim 3 , wherein claim 3 , a specific method for modifying chitosan by hydroxycinnamic acid comprises:1) adding dimethyl sulfoxide into chitosan, stirring, then slowly dropping alkaline solution, and alkalinizing for 1.8-2.2 h by stirring;2) ...

Подробнее
Номер записи: 51
08-04-2021 дата публикации

FIBRINOGEN COMPOSITION, METHOD AND WOUND ARTICLES

Номер: US20210100929A1
Автор: "OHare Jonathan J.", Asmus Robert A., BJORK JAMES W., Determan Amy S., DiZio James P., TIAN ZHICHENG
Принадлежит: 3M INNOVATIVE PROPERTIES COMPANY

Disclosed is a fibrinogen composition. The fibrinogen composition comprises denatured fibrinogen hydrogel having a fibrinogen concentration ranging from 0.1 to 15 wt.-% and a fibrinogen hydrogel forming salt at a concentration less than a threshold concentration to form the fibrinogen hydrogel. In some examples, the fibrinogen composition is dehydrated denatured fibrinogen hydrogel, where the fibrinogen composition comprises salt at a concentration no greater than 20 wt.-%. 1. A fibrinogen composition comprisingdenatured fibrinogen hydrogel having a fibrinogen concentration ranging from 0.1 to 15 wt.-%;fibrinogen hydrogel forming salt at a concentration less than a threshold concentration to form the fibrinogen hydrogel.2. The fibrinogen composition of claim 1 , wherein the fibrinogen composition comprises at least 50 wt.-% water.3. The fibrinogen composition of claim 1 , wherein the fibrinogen hydrogel forming salt concentration is less than 0.45 wt-% of the fibrinogen composition.4. The fibrinogen composition of claim 1 , wherein the fibrinogen hydrogel forming salt comprises sodium citrate optionally in combination with sodium chloride.5. The fibrinogen composition of claim 1 , further comprising a plasticizer.6. The fibrinogen composition of wherein the plasticizer comprises a sugar alcohol claim 5 , an alkane diol claim 5 , or a combination thereof.7. The fibrinogen composition of claim 1 , further comprising a carrier material in an amount ranging from 0.1 to about 50 wt.-%.8. The fibrinogen composition of wherein the carrier material comprises a water-soluble polymer.9. The fibrinogen composition of claim 8 , wherein the water-soluble polymer comprises polymerized units of N-vinyl lactam polymer.10. The fibrinogen composition of claim 7 , wherein the carrier material further comprises a swelling agent.11. The fibrinogen composition of claim 1 , wherein the fibrinogen composition is at least partially dehydrated.12. A fibrinogen composition ...

Подробнее
Номер записи: 52
19-04-2018 дата публикации

Composition for Covering and Protecting Scars

Номер: US20180104379A1
Автор: SCHMID Juerg, Supersaxo Andreas
Принадлежит:

Subject of the invention is a composition comprising: (a) at least one film-forming polymer, which does not comprise silicon, (b) at least one organic UV filter, and (c) at least one organic solvent, wherein the composition is liquid at 20° C., wherein components (a) and (b) are dissolved in solvent (c), and wherein the ratio of the total amounts of organic UV filters (b) to film-form ing polymers (a) is below 6.5. The invention also relates to compositions for therapy, uses of the composition, devices and methods. 1. A composition comprising(a) at least one film-forming polymer, which does not comprise silicon,(b) at least one organic UV filter, and(c) at least one organic solvent,wherein the composition is liquid at 20° C., wherein components (a) and (b) are dissolved in solvent (c), andwherein the ratio of the total amounts in weight percent of organic UV filters (b) to film-forming polymers (a) is below 6.5,wherein the overall amount of UV filters (b) in the composition is at least 10% (w/w).25-. (canceled)6. The composition of claim 1 , wherein the film-forming polymer (a) is an amphiphilic copolymer.7. The composition of claim 1 , wherein the film-forming polymer (a) is an acrylate/amide copolymer with alkyl groups having 6 to 16 carbon atoms.8. The composition of claim 1 , wherein the composition comprises at least 5% (w/w) of film-forming polymers (a) claim 1 , and/or wherein the composition comprises less than 5% (w/w) water claim 1 , and/orwherein the ratio of the total amounts in weight percent of organic UV filters (b) to film-forming polymers (a) is above 1.9. The composition of claim 1 , wherein the solvent (c) is an aliphatic alcohol claim 1 , and/orwherein the composition comprises at least one additive (d).10. The composition of claim 1 , consisting of(a) between 5 and 50% (w/w) film-forming polymers, which do not comprise silicon,(b) between 10 and 60% (w/w) organic UV filters,(c) between 30 and 90% (w/w) organic solvents, and(d) between 0 to 25% ( ...

Подробнее
Номер записи: 53
20-04-2017 дата публикации

Hydrogel Composites, Compositions, and Methods

Номер: US20170106117A1
Автор: Artzi Natalie, Charles Lyndon Fitzgerald, Edelman Elazer Reuven, Strecker Sara Elaine, Unterman Shimon Aryeh
Принадлежит:

Provided herein are methods for treating, adhering, or sealing biological tissue with a material, such as a hydrogel, that may include phyllosilicate nanoplatelets. The phyllosilicate nanoplatelets can have a high aspect ratio, a low aspect ratio, or be a mixture of high aspect ratio and low aspect ratio nanoplatelets. Drug releasing compositions and kits also are provided herein. 1. A method for treating , adhering , or sealing biological tissue , the method comprising:providing a first solution comprising a first polymer component comprising a first polymer having one or more aldehydes;providing a second solution comprising at least one of (i) a dendrimer comprising at least two branches with one or more surface groups, wherein about 25% to 100% of the surface groups comprise at least one primary or secondary amine, and (ii) a second polymer component comprising a second polymer having one or more amines;combining the first and second solutions together to produce a hydrogel composite; andcontacting one or more biological tissues with the hydrogel composite,wherein at least one of the first solution and the second solution comprises phyllosilicate nanoplatelets.2. The method of claim 1 , wherein the phyllosilicate nanoplatelets are substantially evenly dispersed in the first solution claim 1 , the second solution claim 1 , or both the first solution and the second solution.3. The method of claim 1 , wherein the concentration of the phyllosilicate nanoplatelets in at least one of the first solution and the second solution is about 0.01% to about 30% by weight of the first solution or the second solution claim 1 , respectively.4. The method of claim 1 , wherein the phyllosilicate nanoplatelets of at least one of the first solution and the second solution have a low aspect ratio.5. The method of claim 1 , wherein the phyllosilicate nanoplatelets of at least one of the first solution and the second solution have a high aspect ratio.6. The method of claim 1 , wherein ...

Подробнее
Номер записи: 54
29-04-2021 дата публикации

METHODS FOR TREATING WOUNDS

Номер: US20210121601A1
Автор: Lynch Samuel E., Wisner-Lynch Leslie
Принадлежит:

Novel compositions for treating wounds and promoting the healing thereof are described, including composition containing novel combinations of a carrier and recombinant platelet derived grown factor having fewer isoforms and enhanced biostability. Methods of treating wounds with novel therapeutic composition using dosing procedures leading to effective results with a minimal number of treatment applications are also described. 1. A method of treating a wound that extends through the epidermis , wherein said method comprises:(1) debriding the wound to remove necrotic or infected tissue;(2) forming a therapeutic composition consisting essentially of sterile recombinant human PDGF-BB (rhPDGF-BB) in a physiologic solution and a sterile porous biocompatible carrier, wherein the porous biocompatible carrier is a collagen sponge or collagen wound dressing, and said therapeutic composition is free from an enzyme inhibitor;{'sup': '2', '(3) applying the therapeutic composition to the wound surface in an amount that is at least about 10 μg rh PDGF-BB per cmof treated wound surface area, wherein the carrier provides a substrate for cell attachment and vascular ingrowth as the wound heals;'}(4) covering the wound with a dressing; and(5) monitoring the healing of the wound during a treatment period and repeating steps (1)-(4) to retreat the wound at treatment intervals of 7 or more days,{'sup': 2', '2, '(6) wherein the wound is retreated from 2 to 20 times, and wherein each retreatment comprises applying the therapeutic composition to the wound surface in an amount that is at least 10 μg rhPDGF-BB/cmtreated wound surface area up to 100 μg rhPDGF-BB/cmtreated wound surface area.'}2. The method of wherein the wound extends through the epidermis for at least six weeks duration.3. The method of wherein the wound is an ulcer.4. The method of wherein the wound is a diabetic foot ulcer.5. The method of wherein the wound is a venous stasis ulcer.6. The method of wherein the wound is a ...

Подробнее
Номер записи: 55
09-06-2022 дата публикации

Antimicrobial Compositions

Номер: US20220175829A1
Автор: Broughton Mark, Green Stewart, Harding Ian, Richings-Barrow Wendy
Принадлежит:

Liquid compositions are described which have enzyme that is able to convert a substrate to release hydrogen peroxide; substrate for the enzyme; and polymer. The substrate is less than 10% by weight of the composition and the composition does not comprise sufficient free water to allow the enzyme to convert the substrate, or has a water activity of 0.7 or less. 1. A composition comprising:enzyme that is able to convert a substrate to release hydrogen peroxide;substrate for the enzyme, the substrate being less than 10% by weight of the composition; andpolymer,wherein the composition does not comprise sufficient free water to allow the enzyme to convert the substrate or has a water activity of 0.7 or lesswherein the composition is a liquid.2. A composition according to claim 1 , wherein the substrate is at least 1% claim 1 , by weight claim 1 , of the composition claim 1 , preferably at least 2% claim 1 , by weight claim 1 , of the composition.3. A composition according to or claim 1 , comprising solute.4. A composition according to claim 3 , wherein the solute has a solubility of at least 300 g/100 g water at 20° C. and 1 atm.5. A composition according to or claim 3 , wherein the solute is claim 3 , or comprises claim 3 , a sugar or sugar derivative.6. A composition according to any of to claim 3 , wherein the solute is claim 3 , or comprises claim 3 , fructose.7. A composition according to any preceding claim claim 3 , wherein the solute is 50% or less claim 3 , by weight claim 3 , of the composition claim 3 , preferably 45% or less by weight of the composition.8. A composition according to any preceding claim claim 3 , which does not comprise honey.9. A composition according to any preceding claim claim 3 , which comprises substantially no oil or lipophilic phase.10. A composition according to any preceding claim claim 3 , comprising non-aqueous solvent.11. A composition according to claim 10 , wherein the non-aqueous solvent is claim 10 , or comprises claim 10 , a ...

Подробнее
Номер записи: 56
30-04-2015 дата публикации

SOLID DRESSING FOR TREATING WOUNDED TISSUE

Номер: US20150118284A1
Автор: BEALL Dawson, MACPHEE Martin
Принадлежит:

Disclosed are solid dressings for treated wounded tissue in mammalian patients, such as a human, comprising a haemostatic layer consisting essentially of a fibrinogen component and thrombin, wherein the thrombin is present in an amount between 0.250 Units/mg of fibrinogen component and 0.062 Units/mg of fibrinogen component. Also disclosed are methods for treating wounded tissue. 1. A solid dressing for treating wounded tissue in a mammal comprising at least one haemostatic layer consisting essentially of thrombin and a fibrinogen component , wherein said thrombin is present in an amount between about 0.250 Units/mg of fibrinogen component and 0.062 Units/mg of fibrinogen component.2. The solid dressing of claim 1 , further comprising at least one support layer.3. The solid dressing of claim 2 , wherein said support layer comprises a backing material.4. The solid dressing of claim 2 , wherein said support layer comprises an internal support material.5. The solid dressing of claim 2 , wherein said support layer comprises a resorbable material.6. The solid dressing of claim 2 , wherein said support layer comprises a non-resorbable material.7. (canceled)8. The solid dressing of claim 3 , further comprising at least physiologically acceptable adhesive between said haemostatic layer and said backing layer.911-. (canceled)12. The solid dressing of claim 1 , wherein said haemostatic layer also contains a fibrin crosslinker and/or a source of calcium ions.13. The solid dressing of claim 1 , wherein said haemostatic layer also contains one or more of the following: at least one filler claim 1 , at least one solubilizing agent claim 1 , at least one foaming agent and at least one release agent.1417-. (canceled)18. The solid dressing of claim 1 , wherein said haemostatic layer also contains at least one therapeutic supplement selected from the group consisting of antibiotics claim 1 , anticoagulants claim 1 , steroids claim 1 , cardiovascular drugs claim 1 , growth factors ...

Подробнее
Номер записи: 57
13-05-2021 дата публикации

SYSTEMS AND METHODS OF PREPARING AND DELIVERING GELS

Номер: US20210138106A1
Автор: HUTCHINS James
Принадлежит: APPLIED LIFESCIENCES AND SYSTEMS, LLC

The present disclosure provides systems and methods for delivering a gel to a surface. In one embodiment, the system may have a first vessel with a first low viscosity aqueous solution comprising a binder/crosslinking agent; and a second vessel with a second low viscosity aqueous solution comprising a gelling component. The separate first and second low viscosity aqueous solutions are sprayed onto a surface where the solutions mix forming a gel. 1. A system for delivering a gel to a surface comprising:a first vessel containing a binder/crosslinking agent in a first solution;a second vessel containing a gelling component in a second solution; anda delivery device in fluid communication with the first and second vessels, the delivery device having a delivery device outlet.2. The system of whereby when the first solution is moved from the first vessel to the delivery device outlet to create a first spray on a fixed location claim 1 , and the second solution is moved from the second vessel to the delivery device outlet to create a second spray on the fixed location claim 1 , the first and second solutions react to form a gel at the fixed location.3. The system of claim 1 , wherein the gelling component is sodium alginate and the binder/crosslinking agent is calcium chloride.4. The system of claim 1 , wherein the first solution or the second solution further comprise a product of interest as either a solution or a suspension.5. The system of claim 4 , wherein the product of interest has application in at least one of a group of industries consisting of: food claim 4 , agricultural claim 4 , manufacturing claim 4 , chemical claim 4 , biochemical claim 4 , military claim 4 , aerospace claim 4 , pharmaceutical claim 4 , nutraceutical claim 4 , cosmetic claim 4 , printing claim 4 , or a combination thereof.6. The system of claim 4 , wherein the product of interest is an edible claim 4 , a herbicide claim 4 , a pesticide claim 4 , a medicine claim 4 , a biologic claim 4 , a ...

Подробнее
Номер записи: 58
05-05-2016 дата публикации

VACUUM EXPANDED DRY COMPOSITION AND SYRINGE FOR RETAINING SAME

Номер: US20160120527A1
Автор: Larsen Kristian, Mortensen Michael Wrang
Принадлежит:

The present disclosure relates to a method for vacuum expansion of a paste prior to freeze-drying said paste to achieve a dry paste composition which reconstitutes efficiently to form a flowable paste upon addition of an aqueous medium. The present disclosure further relates to a syringe for retaining a dry paste composition in a vacuum. 1. A method for preparing a dry composition comprising the sequential steps of:a) providing an agent in powder form and an aqueous medium,b) mixing the agent in powder form and the aqueous medium to obtain a paste,c) subjecting the paste to a reduced pressure thereby expanding the paste,d) freezing the expanded paste, ande) drying the paste.2. The method according to claim 1 , wherein the reduced pressure is a pressure of at least 10 mbar less than ambient pressure.3. The method according to claim 1 , wherein the volume of the paste is increased by about a factor 1.05 to about a factor 2.0 as a result of the reduced pressure.4. The method according to claim 1 , wherein the density of the paste is decreased by at least a factor 0.95 as a result of the vacuum expansion.5. The method according to claim 1 , wherein the agent in powder form is a biocompatible polymer.6. The method according to claim 1 , wherein the agent in powder form consists of powder particles which are substantially insoluble in an aqueous medium.7. The method according to claim 1 , wherein the agent in powder form is cross-linked.8. The method according to claim 1 , wherein the agent in powder form is biologically absorbable.9. The method according to claim 1 , wherein the agent in powder form comprises or consists of gelatine.10. The method according to claim 9 , wherein the gelatine is obtained from a micronized gelatine sponge which has been cross-linked by dry heat treatment.11. The method according to claim 1 , wherein the mixing in step b) introduces a discontinuous gas phase substantially homogenously dispersed through the paste.12. The method according to ...

Подробнее
Номер записи: 59
03-05-2018 дата публикации

MODIFIED COLLAGEN, METHODS OF MANUFACTURE THEREOF

Номер: US20180118809A1
Автор: MEARNS SPRAGG Andrew
Принадлежит:

The present invention provides a modified collagen comprising S-nitroso groups and a method of manufacture of such a modified collagen. Also provided is a wound dressing comprising such a modified collagen, particularly a wound dressing comprising a formulated composition comprising such a modified collagen. 1. A method of producing a modified collagen , comprising at least the steps of:providing a collagen comprising a S—S bond, such as a collagen of one or more of Type I, II, III, IV, V, VI, IX, X and XI comprising a S—S bond;introducing a —SH group in said collagen comprising a S—S bond by reduction of the S—S bond to provide a collagen thiol comprising a —SH group;nitrosating the —SH group of the collagen thiol to provide a modified collagen, said modified collagen comprising S-nitroso groups.2. The method of wherein the step of providing a collagen comprising a S—S bond claim 1 , comprises at least the steps of:providing a source collagen comprising one or both of lysine and hydroxylysine residues;{'sub': '2', 'reacting the source collagen with an activated dicarboxylic acid derivative comprising a disulphide group to form amide bonds between the carbonyl function of the activated dicarboxylic acid derivative and the c-NHgroups of one or both of the lysine and hydroxylysine residues, thereby providing the collagen comprising a S—S bond.'}3. The method of wherein the activated dicarboxylic acid derivative is a compound of the formula:{'br': None, 'sup': 3', '1', '2', '3, 'ZN—C(O)—R—C(O)—NH—R—S—S—R—NH—C(O)—R—C(O)—NZ \u2003\u2003(I)'}{'sup': 1', '2', '3, 'wherein R, Rand Rindependently represent divalent linking groups; and'}ZN together represent a nitrogen containing heterocyclic group.5. The method of claim 1 , wherein the step of introducing a —SH group in said collagen comprising a S—S bond by reduction of the S—S bond to provide a collagen thiol having a —SH group comprises:reacting the collagen comprising a S—S bond with dithiothreitol.6. The method of claim ...

Подробнее
Номер записи: 60
25-08-2022 дата публикации

Antibiofilm Compositions, Wound Dressings, Cleaning Methods And Treatment Methods

Номер: US20220265894A1
Автор: Hyslop Paul
Принадлежит: Zoono Group Ltd

The patent disclosure covers antibiofilm compositions, wound dressings, cleaning methods and treatment methods. The antibiofilm composition is comprised of between about 0.05% (w/w) to about 0.20% (w/w) benzalkonium chloride; between about 0.20% (w/w) to about 0.50% (w/w) 3-(tri-methoxysilyl)propyldimethyl octadecyl ammonium chloride; between about 0.25% (w/w) to about 0.75% (w/w) phenoxyethanol and between about 98.55% (w/w) to about 99.5% (w/w) deionized water. Disclosed are wound dressings having a reservoir of the antibiofilm composition. In the field of inanimate surfaces, disclosed are methods to clean and clean and protect inanimate surfaces. In the field of animate surfaces, disclosed are methods for the treatment of nose, ear and skin/facial disorders associated with biofilms. 1. An antibiofilm composition comprised of:a between about 0.05% (w/w) to about 0.20% (w/w) benzalkonium chloride;b between about 0.20% (w/w) to about 0.50% (w/w) 3-(tri-methoxysilyl)propyldimethyl octadecyl ammonium chloride;c between about 0.25% (w/w) to about 0.75% (w/w) phenoxyethanol andd between about 98.55% (w/w) to about 99.5% (w/w) deionized water.2. The antibiofilm composition of where the:a the benzalkonium chloride is that of the same which meets the description of Chemical Abstracts Service No. 68424-85-1;b the 3-(tri-methoxysilyl)propyldimethyl octadecyl ammonium chloride is that of the same which meets the description of Chemical Abstracts Service No. 27668-52-6c the phenoxyethanol is that of the same which meets the description of Chemical Abstracts Service No. 122-99-6 andd the deionized water is that of the same which meets the description of Chemical Abstracts Service No. 7732-18-5.3. The antibiofilm composition of having between about 0.05% (w/w) to about 0.15% (w/w) fragrance with there being proportionally less deionized water such that the weight percentage total of all the ingredients is 100%.4. The antibiofilm composition of where the fragrance is selected ...

Подробнее
Номер записи: 61
25-04-2019 дата публикации

Optimal Interstrand Bridge for Collagen Mimics

Номер: US20190119355A1
Автор: RAINES Ronald T., Tanrikulu Ismet C.
Принадлежит:

Novel collagen-mimetic peptides are disclosed comprising the formula (Xaa-Yaa-Gly), where the amino acid at one of the Xaa positions is substituted with a homocysteine residue. Also disclosed are multi-stranded novel collagen-mimetic peptides comprising a first strand as described above that is covalently bonded with a disulfide bridge to a second strand comprising the formula (Xaa-Yaa-Gly), where the amino acid at one of the Yaa positions is substituted with a cysteine residue. Disulfide formation between the terminal thiol sulfur of the homocysteine residue of the first strand and the terminal thiol sulfur of the cysteine residue of the second strand reveals unstrained bridges that enhance the structure and substantially improve the stability of collagen triple helices as compared to other possible disulfide or thioether bridges. Thus, the disclosed collagen mimetic peptides have improved stability, and can be used to produce optimized collagen-like fibrillar assemblies for wound healing and other biomedical applications. 1. (canceled)33. A multistrand collagen-mimetic peptide comprising{'sub': n', 'm', 'n', 'm, '(a) a first strand consisting of the formula (Xaa-Yaa-Gly)-Hcy-Yaa-Gly-(Xaa-Yaa-Gly)or (Xaa-Yaa-Gly)-Cys-Yaa-Gly-(Xaa-Yaa-Gly), wherein Gly is glycine, Hcy is homocysteine, each Xaa and each Yaa is independently any amino acid residue, and (i) n is an integer from 0-16 and m is an integer from 1-16, or (ii) n is an integer from 1-16 and m is an integer from 0-16;'}{'sub': p', 'q', 'r', 'p', 'q', 'r, '(b) a second strand consisting of the formula (Xaa-Yaa-Gly)-Xaa-Cys-Gly-(Xaa-Yaa-Gly)-Hcy-Yaa-Gly-(Xaa-Yaa-Gly)or (Xaa-Yaa-Gly)-Hcy-Yaa-Gly-(Xaa-Yaa-Gly)-Xaa-Cys-Gly-(Xaa-Yaa-Gly), wherein Gly is glycine, Cys is cysteine, each Xaa and each Yaa is independently any amino acid residue, and (i) p, q and r are independently selected from an integer from 0-16;'}wherein n+m+1=p+q+r+2; andwherein the first and second strands are covalently bonded with a disulfide ...

Подробнее
Номер записи: 62
27-05-2021 дата публикации

NANOFIBER-REINFORCED HYDROGEL MEDICAL DRESSINGS

Номер: US20210154356A1
Автор: BRODERICK Keley, COSTELLA Lauren Anne, GASBARRE Mallory, Patterson Matthew, TISON Christopher K., WOODARD Lindsay
Принадлежит:

Medical dressings include a non-woven polymeric nanofiber mat embedded within a chitosan hydrogel matrix. The dressings may be obtained by electro spinning of polymeric nanofibers and thereafter incorporating a chitosan hydrogel into interstices of the mat by vacuum or positive pressure assistance. The resulting medical dressings may be optically transparent (e.g., at least about 50% up to about 95% light transmittance), flexible, and mechanically robust. The dressings may also incorporate self-adhesion promoters to allow self-adhesion to biological tissue, e.g., ocular surfaces, and/or therapeutic agents which are capable of delivering therapeutics (e.g. stem cells, drugs and the like) to the tissue surface. The dressings are especially useful as ocular bandages for the treatment and repair of ocular wounds. 1. A medical dressing comprising a chitosan hydrogel matrix and a non-woven polymeric nanofiber mat embedded in the matrix.2. The medical dressing according to claim 1 , wherein the chitosan hydrogel comprises deacetylated chitosan.3. The medical dressing according to claim 2 , wherein the chitosan hydrogel has a degree of deacetylation (DD) of between about 40 to about 100%.4. The medical dressing according to claim 3 , wherein the chitosan hydrogel is water soluble and has a degree of deacetylation (DD) of between about 40 to about 60%.5. The medical dressing according to claim 3 , wherein the chitosan hydrogel is acid soluble and has a degree of deacetylation (DD) of between about 85 to about 100%.6. The medical dressing according to claim 1 , wherein the chitosan hydrogel has a molecular weight (M) between 50 claim 1 ,000 and 375 claim 1 ,000 g/mol.7. The medical dressing according to claim 6 , wherein the chitosan hydrogel comprises glycerol as a plasticizing agent in an amount up to 5% v/v.8. The medical dressing according to claim 1 , which further comprises a surface adhesion promoter and/or a therapeutic agent.9. The medical dressing according to claim ...

Подробнее
Номер записи: 63
14-05-2015 дата публикации

HEMOSTATIC PRODUCTS

Номер: US20150132361A1
Автор: Floyd Tim, Messina Phil, Olson Curtis
Принадлежит:

A method of inducing hemostasis in a wound. A hemostatic product is applied to a wound. The hemostatic product includes at least one hemostasis component. The hemostatic product is retained with respect to the wound by positioning a hydrogel material at least partially over the hemostatic product. At least a portion of the hemostatic product is dissolved. Hemostasis is induced in the wound with the at least one hemostasis component. The hydrogel material is separated from the wound. Substantially all of the hemostatic product remains on the wound. 1. A method of inducing hemostasis in a wound comprising:applying a hemostatic product to a wound, wherein the hemostatic product comprises at least one hemostasis component;retaining the hemostatic product with respect to the wound by positioning a hydrogel material at least partially over the hemostatic product;dissolving at least a portion of the hemostatic product;inducing hemostasis in the wound with the at least one hemostasis component; andseparating the hydrogel material from the wound, wherein substantially all of the hemostatic product remains on the wound.2. The method of inducing hemostasis of claim 1 , wherein the hemostatic product comprises an electrospun dextran support on which the at least one hemostasis component is associated claim 1 , wherein the at least one hemostasis component comprises at least one of thrombin and fibrinogen.3. The method of inducing hemostasis of claim 1 , wherein the hydrogel material comprises:at least one hydrophilic polymer; anda reinforcing material to which the hydrophilic polymer is associated.4. The method of inducing hemostasis of claim 3 , wherein reinforcing material comprises mesh.5. The method of inducing hemostasis of claim 1 , and further comprising associating a backing material with the hydrogel material.6. The method of inducing hemostasis of claim 5 , wherein the backing material resists separation from the hydrogel material when the hydrogel material is removed ...

Подробнее
Номер записи: 64
14-05-2015 дата публикации

SOLID DRESSING FOR TREATING WOUNDED TISSUE

Номер: US20150132363A1
Автор: BEALL Dawson, MACPHEE Martin
Принадлежит:

Disclosed are solid dressings for treated wounded tissue in mammalian patients, such as a human, comprising a haemostatic layer consisting essentially of fibrinogen and a fibrinogen activator, wherein the fibrinogen is present in an amount between 3.0 mg/cmof the wound facing surface of the dressing and 13.0 mg/cmof the wound facing surface of the dressing. Also disclosed are methods for treating wounded tissue. 1. A solid dressing for treating wounded tissue m a mammal comprising at least one haemostatic layer consisting essentially of fibrinogen and a fibrinogen activator , wherein said fibrinogen is present in an amount between 3.0 mg/cmof the wound facing surface of said dressing and 13.0 mg/cmof the wound facing surface of said dressing.2. The solid dressing of claim 1 , further comprising at least one support layer.3. The solid dressing of claim 2 , wherein said support layer comprises a backing material.4. The solid dressing of claim 2 , wherein said support layer comprises an internal support material.5. The solid dressing of claim 2 , wherein said support layer comprises a resorbable material.6. The solid dressing of claim 2 , wherein said support layer comprises a non-resorbable material.7. (canceled)8. The solid dressing of claim 3 , further comprising at least physiologically acceptable adhesive between said haemostatic layer and said backing layer.911-. (canceled)12. The solid dressing of claim 1 , wherein said haemostatic layer also contains a fibrin crosslinker and/or a source of calcium ions.13. The solid dressing of claim 1 , wherein said haemostatic layer also contains one or more of the following: at least one filler claim 1 , at least one solubilizing agent claim 1 , at least one foaming agent and at least one release agent.1417-. (canceled)18. The solid dressing of claim 1 , wherein said haemostatic layer also contains at least one therapeutic supplement selected from the group consisting of antibiotics claim 1 , anticoagulants claim 1 , ...

Подробнее
Номер записи: 65
12-05-2016 дата публикации

SUGAR CHAIN-POLYPEPTIDE COMPLEX

Номер: US20160129150A1
Автор: OCHIAI Hirofumi, SAIJO Hayato, SHIMODA Taiji, Tazuru Keisuke
Принадлежит:

The object of the present invention is to provide a sugar chain-polypeptide complex that may form a transparent and homogeneous hydrogel in a broad pH. The present invention provides a sugar chain-polypeptide complex, characterized in that said polypeptide is a polypeptide comprising an amino acid sequence consisting of 8-34 amino acid residues in which polar and nonpolar amino acid residues are alternately arranged, and one or more sugar chains are bound to said polypeptide. 1. A sugar chain-polypeptide complex characterized in thatsaid polypeptide is a polypeptide comprising an amino acid sequence consisting of 8-34 amino acid residues in which polar and nonpolar amino acid residues are alternately arranged, andone or more sugar chains are bound to said polypeptide.2. The sugar chain-polypeptide complex according to claim 1 , characterized in that said sugar chain-polypeptide complex may form a hydrogel comprising a β sheet structure by self-assembly in an aqueous solution having a pH around neutral.3. The sugar chain-polypeptide complex according to claim 1 , characterized in that each of said polar amino acid residue is an amino acid residue selected from the group consisting of an aspartate residue claim 1 , a glutamate residue claim 1 , an arginine residue claim 1 , a lysine residue claim 1 , a histidine residue claim 1 , a tyrosine residue claim 1 , a serine residue claim 1 , a threonine residue claim 1 , an asparagine residue claim 1 , a glutamine residue claim 1 , and a cysteine residue.4. The sugar chain-polypeptide complex according to or claim 1 , characterized in that each of said nonpolar amino acid residue is an amino acid residue selected from the group consisting of an alanine residue claim 1 , a valine residue claim 1 , a leucine residue claim 1 , an isoleucine residue claim 1 , a methionine residue claim 1 , a phenylalanine residue claim 1 , a tryptophan residue claim 1 , a proline residue claim 1 , and a glycine residue.5. The sugar chain- ...

Подробнее
Номер записи: 66
10-05-2018 дата публикации

Materials for tissue regeneration

Номер: US20180125990A1
Автор: Guillermo A. Ameer, Milan Mrksich, Yunxiao ZHU, Zdravka CANKOVA
Принадлежит: Northwestern University

Provided herein are materials for the promotion of tissue regeneration, and methods of promoting tissue regeneration and wound healing therewith. In particular, materials displaying laminin-derived peptide sequences that facilitate cell migration into the material, and methods of use thereof, are provided.

Подробнее
Номер записи: 67
02-05-2019 дата публикации

METHODS FOR TREATING WOUNDS

Номер: US20190125926A1
Автор: Lynch Samuel E., Wisner-Lynch Leslie
Принадлежит:

Novel compositions for treating wounds and promoting the healing thereof are described, including composition containing novel combinations of a carrier and recombinant platelet derived grown factor having fewer isoforms and enhanced biostability. Methods of treating wounds with novel therapeutic composition using dosing procedures leading to effective results with a minimal number of treatment applications are also described. 1. A method of treating a wound that extends through the epidermis , wherein said method comprises:(1) debriding the wound to remove necrotic or infected tissue;(2) forming a therapeutic composition consisting essentially of sterile recombinant human PDGF-BB (rhPDGF-BB) in a physiologic solution and a sterile porous biocompatible carrier, wherein the porous biocompatible carrier is a collagen sponge or collagen wound dressing, and said therapeutic composition is free from an enzyme inhibitor;{'sup': '2', '(3) applying the therapeutic composition to the wound surface in an amount that is at least about 10 μg rh PDGF-BB per cmof treated wound surface area, wherein the carrier provides a substrate for cell attachment and vascular ingrowth as the wound heals;'}(4) covering the wound with a dressing; and(5) monitoring the healing of the wound during a treatment period and repeating steps (1)-(4) to retreat the wound at treatment intervals of 7 or more days,{'sup': 2', '2, '(6) wherein the wound is retreated from 2 to 20 times, and wherein each retreatment comprises applying the therapeutic composition to the wound surface in an amount that is at least 10 μg rhPDGF-BB/cmtreated wound surface area up to 100 μg rhPDGF-BB/cmtreated wound surface area.'}2. The method of wherein the wound extends through the epidermis for at least six weeks duration.3. The method of wherein the wound is an ulcer.4. The method of wherein the wound is a diabetic foot ulcer.5. The method of wherein the wound is a venous stasis ulcer.6. The method of wherein the wound is a ...

Подробнее
Номер записи: 68
17-05-2018 дата публикации

WOUND TREATMENT

Номер: US20180133326A1
Автор: CLARK Rachael L., DELBONO Michelle, Lowing Paul Howard, McInroy Lorna, Nisbet Lorraine
Принадлежит:

Use of a moulding composition comprising a polymer and a setting agent for wound debridement, wherein said use comprises adding water to said moulding composition to form a moulding fluid, applying said moulding fluid to a surface of a wound, allowing said moulding fluid to set in contact with said surface to form a solid covering on said surface, followed by removing said solid covering from the wound. The alginate composition adheres strongly to bacterial biofilms on the wound, whereby the biofilms are removed with the alginate composition. The moulding composition may be used in conjunction with a staining agent that undergoes a colour change in the presence of bacteria or bacterial polysaccharides to show the presence and removal of the biofilm. Also provided are methods of treating wounds using the compositions. 114-. (canceled)15. A kit comprising a moulding composition and instructions for performing a method for treating a wound; wherein the moulding composition comprises a water soluble polymer and a setting agent , the polymer comprises at least one polyanionic polysaccharide , and the setting agent comprises a divalent metal salt; and wherein the instructions compriseadding water to the moulding composition to form a moulding fluid, wherein the polymer and the setting agent are solids, and the moulding fluid comprises a solids to water ratio by weight of between 1:1 and 3:1;applying the moulding fluid to a surface of the wound;allowing the moulding fluid to set in contact with the surface to form a solid covering; andremoving the solid covering from the wound to debride the wound, wherein the removing is performed not more than six hours after the applying.16. The kit of claim 15 , wherein the kit further comprises a staining agent packaged separately from the water soluble polymer and the setting agent claim 15 , wherein the staining agent is adapted to undergo a colour change in the presence of bacteria or bacterial polysaccharides.17. The kit of claim ...

Подробнее
Номер записи: 69
07-08-2014 дата публикации

Device For Promotion Of Hemostasis And/or Wound Healing

Номер: US20140220130A1
Автор: Kristian Larsen, Mads Sabra
Принадлежит: Ferrosan Medical Devices AS

The present invention relates to a matrix material comprising a pharmaceutical composition such as a matrix material with a pharmaceutical composition printed on the surface. In one embodiment the pharmaceutical composition comprises thrombin. The invention further describes a method for making the matrix material with a pharmaceutical composition printed on the surface. In one specific embodiment the invention also relates to the use of said matrix material for promotion of hemostasis and/or wound healing. The invention also relates to a kit-of-parts comprising a matrix with a pharmaceutical composition and a container with a peelable lid.

Подробнее
Номер записи: 70
08-09-2022 дата публикации

ELASTOMER COMPOSITION

Номер: US20220280685A1
Автор: GUILLAMAUD Christelle Marie Aline
Принадлежит: URGO RECHERCHE INNOVATION ET DEVELOPPEMENT

A composition based on triblock copolymers of the ABA type, including two styrene thermoplastic terminal blocks A, glassy at use temperature, and an elastomeric central block B which is a saturated olefin, at least one linear polymer of the polyisobutene type having a very low molecular weight and specific crosslinked polymer particles. The composition exhibits advantageous adhesion and holding properties on the skin which are similar to the properties obtained by matrices based on silicone elastomers. They also exhibit particularly interesting cohesion. 116.-. (canceled)17. A composition comprising:2.5 to 20% of a styrene—saturated olefin—styrene triblock copolymer{'sup': −1', '−1, '30 to 96.5% by weight of a polyisobutene with a number molecular weight of between 700 g·moland 3000 g·mol, and'}1 to 25% by weight of particles of a crosslinked polymer having a carboxylate group density of between 2.0 and 12.0 meq/g and an average pore size of between 0.005 and 1.0 μm, the percentages being expressed by weight, relative to the total weight of the composition.18. The composition according to claim 17 , wherein the amount of styrene—saturated olefin—styrene triblock copolymer is between 3 and 15% by weight claim 17 , preferably between 3.5 and 10% claim 17 , more preferably between 4 and 8% by weight claim 17 , relative to the total weight of the composition.19. The composition according to claim 17 , wherein the triblock copolymer of the styrene—saturated olefin—styrene type is a SEBS or a SEEPS.20. The composition according to claim 17 , wherein the PIB is contained in an amount of 30 to 65% claim 17 , preferably 40 to 60% claim 17 , more preferably 45 to 55% of PIB by weight claim 17 , relative to the total weight of the composition.21. The composition according to claim 17 , wherein the number molecular weight of the PIB is between 700 g·moland 3000 g·mol claim 17 , preferably between 750 g·moland 1500 g·mol claim 17 , more preferably between 800 g·moland 1400 g·mol ...

Подробнее
Номер записи: 71
26-05-2016 дата публикации

ANTIMICROBIAL COMPOSITIONS COMPRISING HYPOCHLOROUS ACID AND SILVER

Номер: US20160143944A1
Автор: PANICHEVA Svetlana, Sampson Mark N., Stapleton Ronan
Принадлежит:

The present invention relates to methods and compositions for treating a surface characterized by microbial infection or colonization. Particularly, the methods of the present invention involve applying a hypohalous acid (e.g., hypochlorous acid) composition and a silver additive. The present invention is useful, for example, in disinfecting or cleaning a mammalian tissue, such as a wound or burn, or disinfecting or cleaning a hard surface, such as a medical device. 1. A method for treating a surface characterized by microbial infection or colonization , comprising applying a hypochlorous acid (HOCl) composition and a silver additive to the surface , thereby reducing the microbial infection or colonization.2. The method of claim 1 , wherein the surface is a hard surface.3. The method of claim 2 , wherein the surface is a tubing claim 2 , contact lens claim 2 , dental prosthesis claim 2 , orthodontic device claim 2 , surgical instrument claim 2 , dental instrument claim 2 , medical examination surface claim 2 , bathroom surface claim 2 , dental water line claim 2 , fabric claim 2 , or bandage or tissue dressing.4. The method of claim 1 , wherein the surface is a medical device.5. The method of claim 4 , wherein the medical device is a urinary catheter claim 4 , mucous extraction catheter claim 4 , suction catheter claim 4 , umbilical cannula claim 4 , intrauterine device claim 4 , intravaginal device claim 4 , intraintestinal device claim 4 , endotracheal tube claim 4 , bronchoscope claim 4 , endoscope claim 4 , electrodes claim 4 , or external prosthesis.6. The method of claim 1 , wherein the surface is a human or animal tissue or organ.7. The method of claim 6 , wherein the surface is a wound or burn.8. The method of any one of to claim 6 , wherein the surface is characterized by bacterial biofilm formation.9. The method of any one of to claim 6 , wherein the HOCl and silver additive are applied in a single composition.10. The method of any one of to claim 6 , ...

Подробнее
Номер записи: 72
26-05-2016 дата публикации

Nanocomposite Hydrogels

Номер: US20160144068A1
Автор: Avery Reginald Keith, Gaharwar Akhilesh K., Khademhosseini Alireza, McKinley Gareth H., Olsen Bradley David
Принадлежит:

Provided herein are hemostatic compositions useful for treating wounds in a patient in need thereof. An exemplary hemostatic comprises gelatin or a derivative thereof and silicate nanoparticles. Methods of use, kits comprising the compositions, and a process of making the compositions are also provided. 1. A pharmaceutical composition , comprising gelatin or a derivative thereof , and silicate nanoparticles.2. The composition of claim 1 , wherein the composition comprises about 0.5 percent to about 85 percent by weight of gelatin or a derivative thereof claim 1 , and silicate nanoparticles together.312.-. (canceled)13. The composition of claim 1 , wherein the composition comprises about 0.5 percent to about 70 percent by weight of the gelatin or a derivative thereof.1420.-. (canceled)21. The composition of claim 1 , wherein the ratio of silicate nanoparticles to gelatin or a derivative thereof claim 1 , is from about 0.1 to about 1.0.22. The composition of claim 1 , wherein the composition further comprises water.2330.-. (canceled)31. The composition of claim 22 , wherein the composition is a hydrogel.32. The composition of claim 1 , wherein the composition comprises a gelatin derivative.33. The composition of claim 32 , wherein the gelatin derivative is methacrylated gelatin (GelMA) claim 32 , acrylated gelatin claim 32 , or thiolated gelatin.34. (canceled)35. The composition of claim 1 , wherein the silicate nanoparticles comprise silicate nanoplatelets.36. The composition of claim 35 , wherein the silicate nanoplatelets comprise a positively charged edge and a negatively charged surface.37. The composition of claim 1 , wherein the overall charge of the silicate nanoparticles is negative.38. The composition of claim 1 , wherein the silicate nanoparticles are from about 5 nm to about 60 nm in diameter.39. (canceled)40. (canceled)41. The composition of claim 1 , wherein the silicate nanoparticles are from about 0.5 nm to about 2 nm in thickness.42. (canceled)43. The ...

Подробнее
Номер записи: 73
04-06-2015 дата публикации

FORMED SHEET PRODUCT AND HEMOSTATIC MATERIAL

Номер: US20150151020A1
Автор: Akiyama Yusuke, Fujinaga Kentaro, HIRASHIMA MASAKI, HONDA Susumu, Imamura Takayuki, Kageyama Yukako, Kaneko Hiroaki, Kawamura Ryoichi, OONO Akitoshi, Satake Makoto, YAMAGUCHI Ayuko
Принадлежит:

A formed sheet product of a polymer composition comprising at least one protein selected from the group consisting of fibrinogen and thrombin and at least one polymer selected from the group consisting of an aliphatic polyester and a water-soluble polymer, and a laminated formed sheet product comprising a first polymer composition layer composed of fibrinogen and a water-soluble polymer and a second polymer composition layer composed of thrombin and an aliphatic polyester are provided. These formed products are applied onto a wound site and function as a hemostatic material. 1. A formed sheet product of a polymer composition comprising at least one protein selected from the group consisting of fibrinogen and thrombin and at least one polymer selected from the group consisting of an aliphatic polyester and a water-soluble polymer.2. The formed sheet product according to claim 1 , wherein the at least one polymer selected from the group consisting of an aliphatic polyester and a water-soluble polymer is selected from the group consisting of a cellulose derivative claim 1 , a polymer having an N-vinyl cyclic lactam unit claim 1 , polyethylene oxide claim 1 , polyvinyl alcohol claim 1 , hyaluronic acid claim 1 , dextran claim 1 , pullulan claim 1 , starch claim 1 , and a mixture thereof.3. The formed sheet product according to claim 1 , wherein the at least one polymer selected from the group consisting of an aliphatic polyester and a water-soluble polymer is selected from the group consisting of hydroxypropyl cellulose claim 1 , methyl cellulose claim 1 , hydroxyethyl cellulose claim 1 , hydroxypropylmethyl cellulose claim 1 , sodium carboxymethyl cellulose claim 1 , and a mixture thereof.4. The formed sheet product according to claim 1 , wherein the at least one polymer selected from the group consisting of an aliphatic polyester and a water-soluble polymer is selected from the group consisting of polyglycolic acid claim 1 , polylactic acid claim 1 , polycaprolactone ...

Подробнее
Номер записи: 74
02-06-2016 дата публикации

POLY(OLIGOETHYLENE GLYCOL METHACRYLATE) HYDROGEL COMPOSITIONS, AND METHODS OF USE THEREOF

Номер: US20160151535A1
Автор: Bakaic Emilia, Deng Xudong, Hoare Todd, Smeets Niels M.B.
Принадлежит:

The present application relates to hydrogel compositions comprising first and second precursor polymers, wherein the precursor polymers are modified poly(oligoethylene glycol methacrylate) copolymers that are crosslinked through electrophile-nucleophile reactions. 1. A hydrogel composition , comprisinga. at least one first precursor polymer which is a nucleophile-functionalized poly(oligoethylene glycol methacrylate) copolymer, andb. at least one second precursor polymer which is an electrophile-functionalized poly(oligoethylene glycol methacrylate) copolymer,wherein the first and second precursor polymers are crosslinked through covalent bonds by reaction of the nucleophilic and electrophilic moieties.2. The hydrogel composition of claim 1 , wherein the nucleophile-functionalized poly(oligoethylene glycol methacrylate) copolymer comprises a nucleophilic moiety which is a hydrazide or amine derivative claim 1 , a carbonyl hydrate claim 1 , an alcohol claim 1 , cyanohydrin or cyanohydrin derivative claim 1 , a thiol or thiol derivative claim 1 , or a phosphorus ylide or derivatives thereof.3. The hydrogel composition of claim 2 , wherein the nucleophilic moiety is a hydrazide moiety.4. The hydrogel composition of claim 1 , wherein the electrophile-functionalized poly(oligoethylene glycol methacrylate) polymer comprises an electrophilic moiety which is an aldehyde claim 1 , a ketones claim 1 , a carboxylic acid claim 1 , an ester claim 1 , an amides claim 1 , a maleimide claim 1 , an acyl (acid) chloride claim 1 , an acid anhydride or an alkene group or derivatives thereof.5. The hydrogel composition of claim 4 , wherein the electrophilic moiety is an aldehyde or ketone moiety.6. The hydrogel composition of claim 1 , wherein the composition comprisesa. at least one first precursor polymer which is a hydrazide-functionalized poly(oligoethylene glycol methacrylate) copolymer, andb. at least one second precursor polymer which is an aldehyde- and/or ketone-functionalized ...

Подробнее
Номер записи: 75
16-05-2019 дата публикации

METHODS OF DEBRIDEMENT OF CHRONIC WOUNDS

Номер: US20190142910A1
Автор: ASCULAI Eilon, BARTFELD Deborah Hanah, GEBLINGER Dafna, Lozinsky Evgenia
Принадлежит:

Methods for wound debridement and specifically methods of debridement of chronic wounds. These methods provide topically applying to a wound site a debriding formulation in the form of a hydrogel that includes a proteolytic enzyme mixture obtained from bromelain and a water-soluble gelling agent, with the debriding formulation being applied to the wound site up to ten times over a period of up to four weeks, thereby achieving debridement of chronic wounds. 135. to . (canceled)36. A method for debridement of a wound comprising topically applying to the wound site of a subject in need of such treatment a therapeutically effective amount of a debriding formulation in a regimen of up to ten applications during a time period of up to four weeks , wherein the debriding formulation formulated in the form of a hydrogel comprising: (i) a proteolytic enzyme mixture obtained from bromelain comprising stem bromelain (EC 3.4.22.32) and ananain (EC 3.4.22.31); and (ii) a water-soluble gelling agent , wherein the water-soluble gelling agent is other than a cross-linked polymer of acrylic acid , and wherein said debriding formulation is maintained in contact with the wound site for at least four hours per application.37. The method according to claim 36 , wherein the wound is a chronic wound.38. The method according to claim 37 , wherein the chronic wound is selected from the group consisting of a diabetic ulcer claim 37 , a venous stasis ulcer claim 37 , an arterial insufficiency ulcer claim 37 , a pressure ulcer claim 37 , a post-operative wound claim 37 , and a post-trauma wound.39. The method according to claim 36 , wherein applying the debriding formulation is performed in a regimen of up to ten applications claim 36 , and wherein the debriding formulation is maintained in contact with the wound site for about 24 hours per application.40. The method according to claim 36 , wherein applying the debriding formulation is performed in a regimen of up to 10 applications claim 36 , ...

Подробнее
Номер записи: 76
07-05-2020 дата публикации

Dry composition for use in haemostasis and wound healing

Номер: US20200140625A1
Автор: Flemming Reissig Jensen, Kristian Larsen, Michael Wrang Mortensen
Принадлежит: Ferrosan Medical Devices AS

The present disclosure relates to a dry composition which reconstitutes without mechanical mixing to form a flowable paste having a soft and light consistency suitable for use in haemostasis and wound healing procedures upon addition of an aqueous medium. The disclosure further relates to methods of preparing the dry composition, methods for reconstituting the dry composition and medical use of the composition.

Подробнее
Номер записи: 77
09-06-2016 дата публикации

Dry haemostatic composition

Номер: US20160158407A1
Автор: Larsen Kristian
Принадлежит:

The present invention relates to a dry composition, which upon addition of an aqueous medium forms a substantially homogenous paste suitable for use in haemostasis procedures. The paste forms spontaneously upon addition of the liquid, hence no mechanical mixing is required for said paste to form. The invention further relates to methods of preparing said dry composition, a paste made from said dry composition and use of said paste for medical and surgical purposes. 1. A method of preparing a dry composition comprising the sequential steps of:a) providing a biocompatible polymer in powder form, one or more polyols and an aqueous medium,b) mixing the biocompatible polymer, the one or more polyols and the aqueous medium to obtain a paste, andc) drying the paste.2. The method according to claim 1 , wherein the paste prior to drying comprises from about 3% to about 40% of one or more polyols.3. The method according to claim 1 , wherein the biocompatible polymer is gelatine.4. The method according to claim 1 , wherein the biocompatible polymer is cross-linked.5. The method according to claim 1 , wherein the drying is freeze-drying.6. The method according to claim 1 , wherein the paste prior to drying comprises:a) from about 3% to about 40% of one or more polyols,b) from about 10% to about 60% of biocompatible polymer, andc) from about 50% to about 90% of water.7. The method according to claim 1 , wherein the paste prior to drying comprises:a) from about 5% to about 20% of one or more polyols,b) from about 15% to about 25% of biocompatible polymer, andc) from about 60% to about 80% of water.8. The method according to claim 1 , wherein the composition after drying comprises less than about 5% of water.9. The method according to claim 1 , wherein the one or more polyols is selected from sugar alcohols claim 1 , sugars and/or derivatives thereof.10. The method according to claim 9 , wherein the one or more sugar alcohols is selected from the group consisting of glycol claim 9 ...

Подробнее
Номер записи: 78
07-06-2018 дата публикации

HAEMOSTATIC COMPOSITIONS

Номер: US20180154038A1
Автор: NICHOLS John Benjamin, ZBOZIEN Renata
Принадлежит:

A sterile, ready-to-use, flowable haemostatic composition comprises a soluble haemostatic agent comprising a plurality of carriers and a plurality of fibrinogen binding peptides immobilised to the carrier; a biocompatible liquid; and particles of biocompatible cross-linked polysaccharide suitable for use in haemostasis and which are insoluble in the biocompatible liquid. Such compositions may be used for the control of bleeding, especially in surgical procedures. 1. A sterile , ready-to-use , flowable haemostatic composition comprising:a soluble haemostatic agent comprising a plurality of carriers and a plurality of fibrinogen-binding peptides immobilised to each carrier;a biocompatible liquid; andparticles of a biocompatible cross-linked polysaccharide suitable for use in haemostasis and which are insoluble in the biocompatible liquid.2. The composition according to claim 1 , wherein the haemostatic composition has been sterilized by steam sterilization claim 1 , or by dry-heat sterilization.3. The composition according to claim 1 , wherein the biocompatible liquid provides a continuous liquid phase claim 1 , and the polymer particles are substantially homogenously dispersed throughout the liquid phase.4. The composition according to claim 1 , wherein each carrier of the haemostatic agent comprises a branched core claim 1 , and the fibrinogen-binding peptides are separately covalently attached to the branched core.5. The composition according to claim 4 , wherein the branched core comprises:from two to ten multi-functional amino acid residues, wherein each fibrinogen-binding peptide is separately covalently attached to a multi-functional amino acid residue of the branched core;a plurality of multi-functional amino acid residues, wherein one or more fibrinogen-binding peptides are separately covalently attached to each of at least two adjacent multi-functional amino acid residues of the branched core;a plurality of multi-functional amino acid residues, wherein two ...

Подробнее
Номер записи: 79
08-06-2017 дата публикации

IN-SITU CROSS-LINKABLE POLYMERIC COMPOSITIONS AND METHODS THEREOF

Номер: US20170157286A1
Автор: Landolina Joseph A.
Принадлежит:

A biocompatible polymeric composition for cross-linking in-situ in a wound is disclosed comprising 1) one or more polyanionic polymers such as alginates or hyaluronates, able to be cross-linked the surface of the wound and 2) one or more polycationic polymers such as chitosan or DEAE-Dextran, that assists in the solidification process as well as speeds up hemostasis without the need for applying pressure. The biocompatible polymeric composition may further comprise a cross-linking agent such as aqueous calcium chloride. The invention encompasses an initial polymeric composition, the solidified matrix cross-linked and integrated at the wound site, including the methods of using, applying, and cross-linking the composition. 121.-. (canceled)22. A method of treating a bleed in a patient in need thereof comprising applying to a bleed site a composition comprising:a) about 0.1% to about 5% by weight of sodium alginate;b) about 2% to about 25% by weight of chitosan; andthe balance of the composition is water.23. The method of claim 22 , wherein the composition comprises about 2% to about 5% by weight of sodium alginate.24. The method of claim 22 , wherein the composition comprises 73% to 93% by weight of water.25. The method of claim 22 , wherein the bleed is an arterial bleed claim 22 , a venous bleed claim 22 , a dental bleed or an oral bleed.26. The method of claim 22 , wherein the bleed is an arterial bleed.27. The method of claim 22 , wherein the bleed is a venous bleed.28. The method of claim 22 , wherein the bleed is treated without the need to apply pressure.29. The method of claim 22 , wherein the composition forms a hemostatic matrix after applying to the bleed site.30. The method of claim 22 , wherein the composition solidifies after applying to the bleed site. This application claims the benefit of provisional patent application Ser. No. 61/559,110, filed 13 Nov. 2011, the entire disclosure of which is incorporated herein by reference.The present invention ...

Подробнее
Номер записи: 80
14-05-2020 дата публикации

FORMULATION COMPRISING NANOSTRUCTURED, BIOCOMPATIBLE AND BIOCATALYTIC MATERIAL FOR THE TREATMENT OF WOUNDS AND INFECTIONS

Номер: US20200147259A1
Автор: LÓPEZ-GOERNE Tessy María
Принадлежит:

Formulation comprising nanostructured, biocompatible and biocatalytic material comprising a solid acid consisting of mixed oxides of silica and titania (TiO—SiO); supporting in its dispersed matrix: copper, silver, gold, iron, rutenium, palladium, zinc, manganese, iridium and/or platinum metals at minimal concentrations, for use in the treatment of wounds and infections. 1. A formulation comprising a nanostructured , biocompatible and biocatalytic material consisting of a solid acid made of mixed oxides of silica and titania (TiO—SiO); supporting in its dispersed matrix: copper , silver , gold , iron , rutenium , rhodium , cobalt , zinc , palladium , zinc , manganese , iridium and/or platinum metals at minimal concentrations , for use in the treatment of wounds and infections.2. The formulation for use in the treatment of wounds and infections of claim 1 , wherein the metal supported in the dispersed matrix is acetil platinum acetonate (Pt(acac)).3. The formulation for use in the treatment of wounds and infections of claim 1 , wherein the formulation is in the form of a gel.4. The formulation for use in the treatment of wounds and infections of claim 1 , wherein the formulation is in the form of a liquid.5. The formulation for use in the treatment of wounds and infections of claim 1 , wherein the wounds and infections to be treated are wounds and infections of patients diagnosed with Diabetes Mellitus. This invention relates to a formulation comprising a nanostructured biocompatible and biocatalytic material to be employed in the treatment and care of wounds and infections of the skin of animals and humans.Wounds and infections are a serious health problem, specially for patients suffering Diabetes Mellitus. Diabetic patients may suffer with a diminished neurocapacity and immune response and thereby are prone to develop wounds and those wounds may easily get infected, these wounds and infections are usually found in the foot of diabetic patients which results in ...

Подробнее
Номер записи: 81
24-06-2021 дата публикации

Methods and compositions for wound healing

Номер: US20210186891A1
Автор: Christopher Murphy, Jonathan F. McAnulty, Nicholas Abbott
Принадлежит: IMBED BIOSCIENCES Inc

The present invention relates to methods and compositions for wound healing. In particular, the present invention relates to promoting and enhancing wound healing by utilizing cross-linker covalent modification molecules to attach and deliver wound active agents to a wound. In addition, the present invention provides methods and compositions utilizing oppositely charged polymers to form a polyelectrolyte layer on a wound surface. The invention further relates to incorporating wound active agents into a polyelectrolyte layer for delivery to a wound.

Подробнее
Номер записи: 82
16-06-2016 дата публикации

PROCESS FOR PRODUCING LOW ENDOTOXIN CHITOSAN

Номер: US20160168277A1
Автор: Gladman June, Hardy Craig, Hoggarth Andrew
Принадлежит:

The present invention relates to a process for producing a low endotoxin alkali chitosan, and also to a process for producing low endotoxin neutral chitosan, chitosan salt and chitosan derivatives, and to the products of such processes. The process comprises contacting chitosan with an alkali solution to form a mixture and leaving the mixture for at least about 12 hours. The low endotoxin alkali chitosan may be used the manufacture of other useful chitosan based products. 117-. (canceled)18: A low endotoxin alkali chitosan produced by a process comprising the steps of:(a) contacting chitosan with an alkali solution to form a mixture; and(b) leaving the mixture for at least about 12 hours.19: An alkali chitosan , a neutral chitosan , a chitosan salt , or a chitosan derivative comprising an endotoxin concentration of less than 100 EU/g.2037-. (canceled)38: A low endotoxin chitosan salt of for use as a haemostat for stemming blood flow or for use in a wound dressing for superficial non-life threatening bleeding or life threatening bleeding.39. (canceled)40: A haemostatic wound dressing comprising a low endotoxin chitosan salt of .4142-. (canceled)43: A low endotoxin neutral chitosan claim 18 , a chitosan salt claim 18 , or a chitosan derivative produced by a process comprising the step of contacting an alkali chitosan of with an acid. The present invention relates to a process for producing a low endotoxin alkali chitosan, and also to a process for producing low endotoxin neutral chitosan, chitosan salt and chitosan derivatives, and to the products of such processes.Chitosan is particularly useful in the preparation of haemostatic materials for use in controlling bleeding.Chitosan is a derivative of solid waste from shell fish processing and can be extracted from fungus culture. Chitosan is a water insoluble cationic polymeric material. Before using chitosan in haemostatic materials, it is often first converted into a water soluble salt. This way, the chitosan salt is ...

Подробнее
Номер записи: 83
29-09-2022 дата публикации

KITS, COMPOSITIONS AND METHODS FOR WOUND TREATMENT AND MANAGEMENT

Номер: US20220305172A1
Автор: Saber Shienlin
Принадлежит:

The inventive subject matter provides compositions and methods for transiently or permanently treating or managing an injury. Contemplated compositions are polymerizable in situ over short time periods, even in the presence of blood, without undue exothermic heat. Contemplated compositions may further comprise an anesthetic, an antiseptic, an adhesion promoter, and/or a vasoconstrictor. 1. A method of transiently treating an injury wherein at least one of blood and tissue is exposed comprising:at least partially filing the injury with a polymerizable composition, the polymerizable composition comprising a silicone mixture, wherein the polymerizable composition polymerizes in the presence of the at least one of the blood and the tissue to form an elastic seal;wherein the polymerizable composition comprises a first and a second adhesion promoter that synergistically enhance adhesion of the polymerized composition to skin and/or tissue at the injury; andwherein the seal is removable for subsequent treatment of the injury.2. The method of claim 1 , wherein the silicone mixture comprises: a first silicone elastomer component comprising a first platinum catalyst; and a second silicone elastomer component comprising a silicone crosslinker.3. The method of claim 2 , further comprising applying a base component to the injury prior to at least partially filling the injury with the silicone mixture claim 2 , wherein the base component comprises at least one of an anesthetic claim 2 , an antiseptic claim 2 , an adhesion promoter claim 2 , a catalyst that accelerates polymerization of the polymerizable composition claim 2 , and a vasoconstrictor.4. The method of wherein the platinum catalyst consists of a rhodium complex in vinyl silicone fluid.5. The method of claim 1 , wherein the polymerizable composition comprises a silicone mixture claim 1 , and wherein the silicone mixture comprises(a) a vinyl end-blocked polydimethylsiloxane as a first silicone elastomer component and a ...

Подробнее
Номер записи: 84
30-05-2019 дата публикации

AGAROID COMPOSITIONS AND METHODS OF USE THEREOF

Номер: US20190160200A1
Автор: PROVONCHEE Richard
Принадлежит:

Provided herein are therapeutic and cosmetic methods that utilize an in situ gelling agaroid composition in the form of a water reactive agaroid. The composition described herein is applicable in the fields of wound healing, tissue bulking, bone grafting, and drug delivery. 1. A composition of matter comprising:an agaroid;glycerin; anda glycol, wherein the ratio of glycerin to glycol by volume is in the range of about 99 to 1 to about 30 to 70.2. The composition of claim 1 , wherein the agaroid is selected from the group consisting of agar claim 1 , agarose claim 1 , purified agarose claim 1 , and derivatized agarose.3. The composition of claim 1 , wherein the glycol is selected from the group consisting of ethylene glycol claim 1 , diethylene glycol claim 1 , triethylene glycol claim 1 , trimethylene glycol claim 1 , propylene glycol claim 1 , and butylene glycol.4. The composition of claim 1 , further comprising one or more of a topical steroid claim 1 , a retinoid claim 1 , an imaging contrast agent claim 1 , a radiopaque agent claim 1 , a pigmentation agent claim 1 , a tensioning agent claim 1 , a moisturizing agent claim 1 , an anti-itch agent claim 1 , an anti-acne agent claim 1 , an anti-cellulite agent claim 1 , an anti-scarring agent claim 1 , an anti-inflammatory agent claim 1 , an anti-oxidant claim 1 , an anti-microbial agent claim 1 , a coagulation agent claim 1 , an analgesic and an anesthetic.5. The composition of claim 1 , wherein the concentration of the agaroid in the composition is about 0.1% to about 10% weight-to-volume.6. The composition of claim 1 , further comprising water in an amount not more than 10% by volume of the composition.7. The composition of claim 1 , wherein the ratio of glycerin to glycol by volume is in the range of about 95 to 5 to about 35 to 65.8. The composition of claim 1 , wherein the glycol is propylene glycol.9. The composition of claim 1 , wherein the composition forms a gel upon contact with water claim 1 , when the ...

Подробнее
Номер записи: 85
23-06-2016 дата публикации

Use of a Haemoglobin for the Preparation of Dressings and Resulting Dressings

Номер: US20160175478A1
Автор: Rousselot Morgane, Zal Franck
Принадлежит:

The invention relates to the use of a haemoglobin for the preparation of dressings and to the resulting dressings. 140.-. (canceled)41. A method for the external treatment of open , deep or chronic wounds , or of periodontal diseases , or of a gastric wounds or of tissues , the method comprising administering a dressing comprising a hemoglobin from a vertebrate or invertebrate animal immobilized in a matrix , wherein the matrix is based on polymerized hydrocolloids and wherein the hemoglobin is stable in the matrix , said matrix being physiologically acceptable , and having a water content of from 0 to 98% , and said matrix being formed from a three-dimensional network defining pores , the size of which is from 2 nm to 300 μm.42. The method of claim 41 , wherein the amount of hemoglobin claim 41 , relative to the total dry weight of hemoglobin and of matrix claim 41 , is from 0.1% (w/w) to 60% (w/w).43. The method of claim 41 , wherein the percentage water content is from greater than 50%.44. The method of claim 41 , wherein the hemoglobin is chemically modified or crosslinked human or vertebrate-animal hemoglobin.45. The method of claim 41 , wherein the hemoglobin is an extracellular hemoglobin from an invertebrate animal chosen from the phylum Annelida.46. The method of claim 41 , wherein said matrix is based on chitosan claim 41 , carrageenans claim 41 , carboxymethylcellulose or alginates.47. The method of claim 46 , wherein said matrix is based on calcium alginate claim 46 , and wherein the amount of hemoglobin present in the matrix claim 46 , relative to the total weight of hemoglobin and of the matrix is 55% (w/w) to 85%.48. A dressing comprising extracellular Annelid hemoglobin immobilized and stable in a hydrocolloid network claim 46 , and having a water content of from 0% to 98% claim 46 , said network defining pores claim 46 , the size of said pores being from 2 nm to 1 μm claim 46 , wherein the Annelid hemoglobin is from about 0.1 to about 60% by weight ...

Подробнее
Номер записи: 86
23-06-2016 дата публикации

COMPOSITE MATERIAL FOR TISSUE REPAIR

Номер: US20160175479A1
Автор: Ratcliffe Anthony
Принадлежит:

The present disclosure provides a biocompatible composite and method for its use in repairing tissue defects, including defects in cartilage. The biocompatible composite includes a fibrous polymeric component and a polymerizable agent, which is capable of forming the biocompatible composite in situ at the site of a tissue defect. In embodiments, the repair site at which the biocompatible composite is to be applied may be treated with a priming agent, permitting polymerization of the polymerizable agent to the tissue located at the repair site. 1identifying a tissue defect for repair;applying a fibrous polymeric component in combination with a polymerizable agent to the tissue defect; andreacting the polymerizable agent with tissue at the site of the defect.. A method comprising: The present disclosure pertains to biocompatible composites which may be formed in situ at the site of a tissue defect and their use in repairing defects in tissue. More specifically, the present disclosure is directed to biocompatible composites including both a fibrous polymeric component in combination with a polymerizable agent such as a polymeric hydrogel for use in repairing defects in tissue, including cartilage.Integration of biomaterials with the body is a longstanding problem in medicine. Lack of proper integration with the body sacrifices implant longevity and function. Hard tissues such as cartilage and bone present particular challenges to integration.Every year in the U.S. there are about 570,000 traumatic injuries to knee articular cartilage, many the result of sports and recreational activities, and approximately half of these require some sort of surgery to repair. Those with articular cartilage injuries often face a series of subsequent surgical interventions throughout their lifetimes, only to end up receiving a total knee replacement. Over 300,000 procedures to treat cartilage defects were performed in 1999; over 240,000 total knee replacements were performed in the same ...

Подробнее
Номер записи: 87
11-09-2014 дата публикации

SILVER CONTAINING WOUND DRESSING

Номер: US20140256676A1
Автор: WOODS David Malcolm
Принадлежит: ConvaTec Technologies Inc.

A wound dressing having anti-microbial activity comprises a first fibre capable of bonding with silver (1) cations. The wound dressing comprises a blend of the first fibre to which silver (1) cations are bonded and a second fibre which is substantially free from silver. The wound dressing comprises from 0.01 to 5.0 percent by weight of silver (1) cations, based on the weight of fibre.

Подробнее
Номер записи: 88
11-09-2014 дата публикации

ABSORBENT ARTICLE

Номер: US20140257217A1
Автор: HABAR Gérard
Принадлежит: MICROCAPSULES TECHNOLOGIES

An absorbent article can include, in an immobilized form:

Подробнее
Номер записи: 89
22-06-2017 дата публикации

AUTOASSEMBLING PEPTIDES FOR THE TREATMENT OF PULMONARY LEAKAGE

Номер: US20170173105A1
Автор: Gil Eun Seok, Gilbert Karl Patrick, Kobayashi Satoru, Mehta Manav, TSUKADA Hisashi
Принадлежит:

Materials and methods for treatment of pulmonary leakage are provided. A peptide comprising between about 7 amino acids and about 32 amino acids in a solution may be introduced to a target site. A hydrogel barrier may be provided at the target site in order to treat the pulmonary leakage. 1. A method of treating a pulmonary leakage in a subject , comprising:introducing a delivery device to a target area of the pulmonary leakage of the subject;positioning an end of the delivery device in the target area in which treatment of a pulmonary leakage is desired;administering through the delivery device a solution comprising a self-assembling peptide comprising between about 7 amino acids and 32 amino acids in an effective amount and in an effective concentration to the target area to form a hydrogel barrier under physiological conditions of the target area to treat the pulmonary leakage; andremoving the delivery device from the target area.2. The method of claim 1 , further comprising visualizing a region comprising the target area prior to introducing the delivery device.3. The method of claim 1 , further comprising visualizing a region comprising the target area subsequent to removing the delivery device from the target area.4. The method of claim 1 , further comprising monitoring the target area after removing the delivery device.5. The method of claim 1 , wherein administering the solution comprises applying the solution topically to the target area.6. The method of claim 1 , wherein administering the solution comprises injecting the solution into the target area claim 1 , with overflow to cover the target area topically.7. The method of claim 1 , wherein administering the solution comprises administering the solution in a single dose.8. The method of claim 1 , wherein administering the solution comprises administering the solution in at least two doses.9. The method of claim 1 , wherein the hydrogel barrier provides a burst pressure tolerance of at least 35 cm HO.10. ...

Подробнее
Номер записи: 90
06-06-2019 дата публикации

HEMOSTATIC FLOWABLE

Номер: US20190167840A1
Автор: CENTIS Valérie, DE GASPERIS Alexia, MOURA CAMPOS Doris, Spotnitz William
Принадлежит:

The invention relates to a kit to prepare an hemostatic flowable comprising: —A hemostatic powder having a composition comprising: ∘non-cross-linked collagen of the fibrillar type comprising a content of fibrous collagen and/or fibrillar collagen of at least 70% by weight relative to the total weight of the collagen; ∘at least one monosaccharide; and ∘at least one glycosaminoglycan; —A saline solution to be mixed with the hemostatic powder in order to form the hemostatic flowable. The invention also relates to a method for preparing an hemostatic flowable with such a kit, comprising the steps of: a. Providing the hemostatic powder in a container; b. Adding a quantity of the saline solution in the container enclosing the hemostatic powder, closing and shaking said container in order to promote hydration of the hemostatic powder to form the hemostatic flowable. 1. A kit to prepare an hemostatic flowable comprising: non-cross-linked collagen of the fibrillar type comprising a content of fibrous collagen and/or fibrillar collagen of at least 70% by weight relative to the total weight of the collagen;', 'at least one monosaccharide; and', 'at least one glycosaminoglycan;, 'a hemostatic powder having a composition comprisinga saline solution to be mixed with the hemostatic powder in order to form the hemostatic flowable.2. The kit of claim 1 , wherein in the composition of the hemostatic powder:the collagen is in an amount ranging from 80% to 90% by weight relative to the total weight of the composition of the hemostatic powder;the at least one monosaccharide is in an amount ranging from 1% to 12.5% by weight relative to the total weight of the composition of the hemostatic powder; andthe at least one glycosaminoglycan is in an amount ranging from 2% to 25% by weight relative to the total weight of the composition of the hemostatic powder.3. The kit of claim 1 , wherein in the composition of the hemostatic powder:the collagen is in an amount ranging from 80% to 90% by ...

Подробнее
Номер записи: 91
28-05-2020 дата публикации

COMPOSITIONS AND METHODS FOR TREATING WOUNDS

Номер: US20200164101A1
Автор: Lynch Samuel E.
Принадлежит:

An improvement to the effectiveness or “take” of skin grafts or tissue replacements used to treat wounds is provided. A therapeutic composition comprising recombinant human platelet-derived growth factor BB homodimer (rhPDGF-BB) and a porous biocompatible carrier is first applied to the wound surface, followed by applying a skin substitute or tissue replacements composition. 1. A method of treating a skin wound , the method comprising:(1) debriding the wound to remove necrotic or infected tissue; {'sup': '2', 'the carrier provides a substrate for cell attachment and vascular ingrowth as the wound heals, and said applying delivers at least about 10 μg rhPDGF-BB per cmof wound surface area;'}, '(2) treating the wound surface by applying a sterile therapeutic composition comprising recombinant human platelet-derived growth factor BB homodimer (rhPDGF-BB) and a porous biocompatible carrier to the wound surface,'}(3) optionally covering the wound with a dressing;(4) optionally using a treatment regimen of repeating steps (1)-(3) for up to 20 times at treatment intervals of three or more days; and(5) applying a skin-substitute composition to the treated wound and optionally covering the wound with a second dressing.2. The method of claim 1 , wherein steps (1)-(3) are repeated until granulation tissue covers the treated wound surface.3. The method of claim 1 , wherein the sterile therapeutic composition further comprises a therapeutically effective amount of an angiogenic promoter.4. The method of claim 3 , wherein the angiogenic promoter is selected from the group consisting of a platelet-derived growth factor that is not rhPDGF-BB (PDGF) claim 3 , epidermal growth factor (EGF) claim 3 , fibroblast growth factor (FGF) claim 3 , insulin-like growth factor (IGF) claim 3 , vascular endothelial growth factor (VEGF) claim 3 , transforming growth factor (TGF) claim 3 , keratinocyte growth factor (KGF) claim 3 , hepatocyte growth factor (HGF) claim 3 , stromal cell-derived ...

Подробнее
Номер записи: 92
28-05-2020 дата публикации

COMPOSITIONS FOR TREATING WOUNDS

Номер: US20200164102A1
Автор: JR. SAMUEL E., LYNCH, Wisner-Lynch Leslie
Принадлежит:

Novel compositions for treating wounds and promoting the healing thereof are described, including composition containing novel combinations of a carrier and recombinant platelet derived growth factor having fewer isoforms and enhanced biostability. Methods of treating wounds with novel therapeutic composition using doing procedures leading to effective results with a minimal number of treatment applications are also described. 1. A therapeutic composition consisting of a sterile therapeutic protein component , a sterile porous insoluble matrix component , and optionally additives that facilitate reconstituting lyophilized rhPDGF , buffers , and stabilizing proteins , wherein:(a) the therapeutic protein component is rhPDGF-BB combined with a physiologic solution resulting in a therapeutic solution yielding between about 0.05 mg/ml to about 5 mg/ml of rhPDGF-BB wherein at least 80% of the rhPDGF-BB is unclipped rhPDGF-BB;(b) prior to forming the therapeutic solution, the rhPDGF-BB is biostable and the rhPDGF-BB is capable of retaining at least 80% of its bioactivity when stored for at least about six months;(c) the insoluble matrix component consists of a natural polymer and includes an open porous structure that allow for cell attachment and ingrowth into said pores having pore sizes ranging between 50 μm and 1 mm, or an average pore size of between 50 microns and 500 microns; or wherein the matrix provides an open porous cell scaffold that has a pore size distribution of between about 10 microns to about 2000 microns, and wherein said pores entrap at least about 50% of said rhPDGF within said pores;(d) wherein the insoluble matrix component is wetted with the therapeutic solution; and{'sup': 3', '3, '(e) wherein the composition is adapted for treating wounds by having a ratio of the rhPDGF to the matrix that is between about 75 μg PDGF/cmof matrix to about 225 μg PDGF/cmof matrix.'}2. The therapeutic composition of wherein the therapeutic solution is formed from a ...

Подробнее
Номер записи: 93
29-06-2017 дата публикации

INTERPENETRATING NETWORK HYDROGELS WITH INDEPENDENTLY TUNABLE STIFFNESS

Номер: US20170182209A1
Автор: Branco da Cunha Cristiana, Chaudhuri Ovijit, Mooney David J.
Принадлежит:

Interpenetrating network hydrogels with independently tunable stiffness enhance tissue regeneration and wound healing. 1. A 3-dimensional hydrogel comprising an interpenetrating network of alginate and collagen , wherein the hydrogel comprises a storage modulus of 30 Pa or greater.2. The hydrogel of claim 1 , wherein the hydrogel comprises a storage modulus of 400 Pa or less.3. The hydrogel of claim 1 , wherein the alginate lacks a cell adhesion molecule.4. The hydrogel of claim 3 , wherein the cell adhesion molecule comprises a polypeptide comprising the amino acid sequence claim 3 , arginine-glycine-aspartate (RGD).5. The hydrogel of claim 1 , wherein the hydrogel does not comprise any covalent crosslinks.6. The hydrogel of claim 1 , wherein the alginate is crosslinked to form a mesh structure.7. The hydrogel of claim 6 , wherein the alginate is ionically crosslinked.8. The hydrogel of claim 7 , wherein the alginate is ionically crosslinked by divalent or trivalent cations.9. The hydrogel of claim 8 , wherein the divalent cation comprises Ca.10. The hydrogel of claim 1 , wherein the alginate comprises a molecular weight of at least 100 kDa.11. The hydrogel of claim 1 , wherein the hydrogel comprises a dextran diffusion coefficient of 2.5×10to 1×10cm/s.12. The hydrogel of claim 1 , wherein the hydrogel comprises multidirectional collagen fibrils.13. The hydrogel of claim 1 , wherein the hydrogel comprises a collagen concentration of about 1.5 mg/mL.14. The hydrogel of claim 1 , wherein the hydrogel comprises an alginate concentration of about 5 mg/mL.15. The hydrogel of claim 1 , wherein the hydrogel comprises interconnected pores.16. The hydrogel of claim 15 , wherein the interconnected pores comprise nanopores.17. The hydrogel of claim 1 , wherein the hydrogel comprises a relative concentration of carbon of 10-50% weight/weight; or a relative concentration of oxygen of 50-70% weight/weight; or a relative concentration of potassium of 0.5-2% weight/weight; or a ...

Подробнее
Номер записи: 94
29-06-2017 дата публикации

System and Methods for Treatment of Wounds With Negative Pressure and Peroxy Pyruvic Acid

Номер: US20170182230A1
Автор: Carroll Christopher A., Ingram Shannon C.
Принадлежит:

In one example embodiment, a system for treating a tissue site is disclosed comprising a dressing adapted to contact the tissue site and provide a fluid seal between a therapeutic environment and a local external environment, and a solution source fluidly coupled to the dressing and adapted to deliver an antimicrobial solution comprising a peroxy α-keto carboxylic acid, such as peroxy pyruvic acid, to the tissue interface. The system may further comprise a negative-pressure source fluidly coupled to the dressing and adapted to provide negative pressure to the therapeutic environment after delivery of the antimicrobial fluid to the therapeutic environment. In another example embodiment, a method for treating a tissue site is disclosed comprising positioning a tissue interface to contact the tissue site, covering the tissue interface and the tissue site with a drape to provide a fluid seal between the therapeutic environment and the local external environment, and delivering an antimicrobial solution comprising peroxy α-keto carboxylic acid to the therapeutic environment before providing negative pressure to the therapeutic environment. 1. A system for treating a tissue site , comprising:a dressing including a tissue interface adapted to contact the tissue site and a cover adapted to provide a fluid seal between a therapeutic environment including the tissue interface proximate one side of the cover and a local external environment on the other side of the cover;a positive-pressure source operable to fluidly couple to a solution source and adapted to actuate a solution source for delivering an antimicrobial solution comprising a peroxy α-keto carboxylic acid to the tissue interface; anda negative-pressure source fluidly coupled to the dressing and adapted to provide negative pressure to the therapeutic environment after delivery of the antimicrobial fluid to the therapeutic environment.2. The system according to claim 1 , wherein the negative-pressure source is ...

Подробнее
Номер записи: 95
07-07-2016 дата публикации

BIOPHOTONIC COMPOSITIONS COMPRISING A CHROMOPHORE AND A GELLING AGENT FOR TREATING WOUNDS

Номер: US20160193338A1
Автор: Loupis Nikolaos, Piergallini Remigio, Rastogi Shipra
Принадлежит:

The present disclosure provides biophotonic compositions, kits and their uses. In particular, the biophotonic compositions of the present disclosure are substantially resistant to leaching such that low amounts of chromophores present in the biophotonic composition leach out of the composition. The biophotonic compositions and their uses are useful for promoting repair of non-healing wounds. 12.-. (canceled)3. The method of claim 95 , wherein the biophotonic composition is translucent.45.-. (canceled)6. The method of claim 95 , wherein the gelling agent is a cross-linked polymer.7. (canceled)8. The method of claim 95 , wherein the gelling agent is one or more of a hydrophilic material claim 95 , a hygroscopic material and a hydrated polymer.994.-. (canceled)95. A method for promoting wound healing claim 95 , comprising: at least a first chromophore; and', 'a gelling agent present in an amount sufficient to gel the composition and render the biophotonic composition substantially resistant to leaching such that less than 15% by weight of the total chromophore amount leaches out of the biophotonic composition in use; and, 'applying topically a biophotonic composition to a wound; wherein the biophotonic composition comprisesilluminating said biophotonic composition with light having a wavelength that overlaps with an absorption spectrum of the first chromophore.96. A method as defined in claim 95 , wherein the wound is a non-healing wound.97. (canceled)98. A method as defined in claim 95 , for further stimulating and/or promoting repair at the centre and/or edge of the wound.99. The method of claim 98 , wherein the stimulated repair is delayed at the edge compared to the centre of the wound.100. The method of claim 99 , wherein the stimulated repair is increased at the centre compared to the edge of the wound.101102.-. (canceled)103. The method of claim 96 , wherein the non-healing wound is an activated non-healing wound.104. The method of claim 98 , wherein stimulating ...

Подробнее
Номер записи: 96
05-07-2018 дата публикации

HIGHLY EFFICACIOUS HEMOSTATIC ADHESIVE POLYMER SCAFFOLD

Номер: US20180185543A1
Автор: Ahmad Omar M., Landolina Joseph A.
Принадлежит:

The invention relates to biocompatible polymer gel compositions useful in facilitating and maintaining hemostasis. The biocompatible polymeric gel composition is comprised of (a) one or more than one polyanionic polymer, (b) one or more than one polycationic polymer, and (c) a solvent. A preferred composition includes sodium alginate, chitosan, and water to produce an adhesive hemostatic device that is useful in facilitating and maintaining rapid hemostasis. 1. A polymeric composition comprising:a. about 0.1% to about 5% by weight of one or more than one polyanionic polymer;b. about 5% to about 40% by weight of one or more than one polycationic polymer; andc. about 50% to about 99.9% by weight solvent.2. A polymeric composition of wherein said one or more than one polyanionic polymer comprises sodium alginate claim 1 , wherein said one or more than one polycationic polymer comprises chitosan claim 1 , wherein said solvent is water.3. A polymeric composition of wherein the sodium alginate has a chain length of between about 1 claim 2 ,000 nm and about 3 claim 2 ,000 nm.4. A polymeric composition of wherein the sodium alginate has an average molecular weight of about 100 kDa to about 1 claim 2 ,000 kDa.5. A polymeric composition of wherein the sodium alginate has an average molecular weight of about 500 kDa to about 900 kDa.6. A polymeric composition of wherein the sodium alginate has an average molecular weight of about 800 kDa.7. A polymeric composition of wherein the chitosan has a chain length of between about 2 claim 2 ,000 nm and about 4 claim 2 ,000 nm.8. A polymeric composition of wherein the chitosan has a chain length of between about 2 claim 2 ,800 nm and about 2 claim 2 ,900 nm.9. A polymeric composition of wherein the chitosan has a chain length of about 2 claim 2 ,850 nm.10. A polymeric composition of wherein the chitosan has an average molecular weight of between about 1 kDa to about 2 claim 2 ,000 kDa.11. A polymeric composition of wherein the chitosan ...

Подробнее
Номер записи: 97
14-07-2016 дата публикации

DRESSING COMPOSITIONS AND METHODS

Номер: US20160199534A1
Автор: Anumolu Siva Naga Sree Priya, Gunaseelan Simi, Menjoge Anupa R., Navath Raghavandra, Sinko Patrick J., Stein Stanley
Принадлежит:

Described is a spray-on hydrogel comprising water-soluble PEG polymers that cross-link in situ to form a hydrogel such that the cross-links are reversible. The hydrogel can be useful as a drug delivery composition, wound dressing or surgery adjuvant. Polyethylene glycol polymer and cross-linker solutions are sprayed simultaneously through a common orifice. Cross-linking via formation of thioether or disulfide bonds is initiated upon mixing, providing rapid gelation. The hydrogel components can be derivatized with RGD peptides or analogs thereof to promote retention in/on a body compartment such as the skin, surface of the eye, or a mucosa such as the vaginal mucosa. The cross-links are reversed using a reducing solution enabling easy removal of the hydrogel by dissolution. Processes for preparation of the cross-linker, RGD derivatized PEG and RGD-linked agents are also disclosed. 2. The wound dressing of claim 1 , wherein the polymer is polyethylene glycol.3. The wound dressing of claim 2 , wherein the polyethylene glycol comprising the sulfhydryl claim 2 , thiol claim 2 , or mercaptan moiety forms disulfide bonds.4. The wound dressing of claim 1 , wherein the composition further comprises a drug or a combination of drugs.5. The wound dressing of wherein the polyethylene glycol is derivatized to contain peptide comprising RGD.6. The wound dressing of wherein a drug or drugs are conjugated to the peptide comprising RGD.7. The wound dressing of wherein the peptide comprising RGD further comprises cysteine.8. The wound dressing of wherein the peptide comprising RGD is a linear peptide having an amino acid sequence selected from the group consisting of Arg-Gly-Asp-Cys claim 5 , Gly-Arg-Gly-Asp-Ser claim 5 , and Gly-Arg-Gly-Asp-Ser-Pro.9. The wound dressing of claim 1 , wherein the cross-linker is selected from the group consisting of HO claim 1 , a maleimide terminated polyethylene glycol claim 1 , and a thiopyridine terminated polyethylene glycol.10. The wound dressing ...

Подробнее
Номер записи: 98
27-06-2019 дата публикации

System and Method for Treating a Wound

Номер: US20190192729A1
Автор: GOH Chien Ming, Pirzada Shahzad Saad
Принадлежит: GENADYNE BIOTECHNOLOGIES, INC.

In at least one embodiment there is a wound application comprising at least one film applied over a wound comprising at least 1% green tea, and at least 0.01% sugar, wherein said film comprises a polymeric film comprising united chains and monomeric glucose points. In at least one other embodiment there is a wound application comprising a solution comprising at least trace amounts of colloidal silver, at least trace amounts of sodium chloride, at least trace amounts of dextrose; and water, wherein the colloidal silver, the sodium chloride and the dextrose are dissolved in water. In at least one other embodiment there is an application for treating a wound comprising both a solution comprising at least trace amounts of colloidal silver and a film comprising at least trace amounts of green tea applied over the solution on top of a wound. 1. A process for preparing a wound application comprising:preparing a solution;settling the solution;washing the solution;drying the solution on the applicator;cutting the applicator; andpackaging the applicator for use in treatment.2. The process as in claim 1 , wherein the step of preparing the solution comprises the following steps:boiling water;applying green tea;adding a pre-set amount of sugar;testing a PH of the solution;adding a pre-set amount of Gluconacetobacter xylinus;placing the solution into separate containers; andallow the solution to sit for a predetermined time of at least 7 days.3. The process as in claim 2 , further comprising the step of visually reviewing the solution to determine whether there is sufficient growth.4. The process as in claim 3 , wherein said step of visually reviewing the solution comprises reviewing the color of the solution.5. The process as in claim 4 , further comprising the step of allowing the solution to cure to form a biomass and then removing the biomass from the separate containers and placing the biomass into a single container.6. The process as in claim 5 , further comprising the step ...

Подробнее
Номер записи: 99
30-07-2015 дата публикации

Oxygenated Oil Ointment

Номер: US20150209470A1
Автор: Young John D.
Принадлежит:

An oxygenated oil ointment is made, for example, by stirring or agitating plant-based oil while injecting a gas into the plant-based oil, resulting in a coagulated ointment that is beneficial for topical application. In one example, the plant-based oil is olive oil and the gas includes ozone, which is known to kill pathogens. For some plant-based oils, the ozone increases amounts of peroxide in the plant-based oils. Once the olive oil coagulates with the ozone, the resulting ointment retains some of the ozone gas until the ointment is applied on the skin for treatment of, for example, cuts and sores. In some ointments, the pH of the plant-based oil is increased by adding one or more alkaline materials to the plant-based oil before coagulation occurs. This increase in alkalinity improves the ointment's ability to give off ozone and oxygen. 1. A coagulated composition for topical application , the composition comprising:a plant-based oil mixed with at least 0.01% by weight of an alkaline material; anda gas, the gas infused into the plant-based oil and the alkaline material.2. The coagulated composition of claim 1 , wherein the alkaline material is one or more materials selected from the group consisting of calcium chloride claim 1 , magnesium sulfide claim 1 , sodium meta-silicate claim 1 , and sulfated castor oil.3. The coagulated composition of claim 1 , wherein the alkaline material has a pH of approximately 13 and comprises a mixture made by mixing 750 milliliters of ion-depleted HO having approximately 17 megohms-cm of resistance (e.g. ultra-pure water having an electrical resistance of 16-26 megohms) with 330 milliliters of calcium chloride claim 1 , 660 milligrams of magnesium sulfate claim 1 , 47 claim 1 ,500 milligrams of Sodium silicate pentahydrate claim 1 , and 1000 milligrams sodium benzoate which is heated to 80 degrees Celsius for ten minutes claim 1 , then cooled to room temperature for ten minutes claim 1 , at which time 100 milliliters of sulfated ...

Подробнее
Номер записи: 100